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Abstract
In the United States, influenza causes approximately 36,000 deaths and over 200,000
hospitalizations each year with elderly most often affected. Clostridium difficile infection
(CDI) is another major health care challenge and pressing public health issue associated
with 14,000 deaths and over 335,000 hospitalizations annually. The use of antibiotics has
been implicated in the development of CDI. This study’s purpose was to test the
relationship of seasonal influenza incidence and antiviral/antibiotic use in CDI
development among hospitalized patients. Grounded in the epidemiologic wheel model
of man-environment interactions, this retrospective observational study described and
analyzed data from a proprietary, laboratory, and pharmacy-based system from a cohort
of hospitals. The association between 147 patients with a diagnosis and/or positive test
for influenza, the independent variables of delivery of antivirals/antibiotics (n = 130)
during the patient’s hospitalization, and the dependent variable of positive test or
diagnosis of CDI (n = 17) was tested using multiple logistic regressions. The study results
did not prove to be significant for the 3 research questions, suggesting no impact of
antiviral use (R2 = .05, p = .336), antibiotic use (R2 = .05, p = .290), or antiviral and/or
antibiotic use (R2 = .04, p = .382) on development of CDI within 60 days of discharge.
However, findings indicated that recommended antiviral medication was inconsistently
administered to influenza positive patients and that inappropriate prescribing patterns for
antimicrobial agents coincided with seasonal influenza. Implications for positive social
change include confirming the importance of antibiotic stewardship as an essential aspect
of quality healthcare.

Quantitative Study of Clostridium difficile Incidence Related to Influenza and
Antimicrobial Use
by
Eileen M. Yaeger

MPH, Northern Illinois University, 1997
BS, Northern Illinois University, 1982

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health Epidemiology

Walden University
May 2015

Dedication
This is dedicated to my family; my hubby Bill and my son Sabastian, my Mom,
and especially my Dad who advised me after completing my Masters degree…to maybe
just stop there. My parents have always been my biggest fans by supporting and cheering
me on during every degree I obtained. From them I inherited the strength of
perseverance and the belief you can do anything you dream of and put your mind to. My
hubby and son have shown such patience, and I love them both so much for this gift.

Acknowledgments
I would be absolutely nowhere without the kindness, help, prodding, support, and
wisdom of my Chair Dr. Aimee Ferraro. Dr. Aaron Mendelsohn has proved to be a
wonderful methods person, challenging me to think and rethink many aspects of my
dissertation. Thank you Dr. Scott McDoniel for your prompt reviews and the thoughtful
edits you provided to fine tune my dissertation. I would like to also acknowledge my
friend and colleague Chad (Dr. Spangler), who provided the key article that started my
area of inquiry and my friend Ed K. who has been my rock and sounding board for
statistics. My Intensive instructors Dr. William Barkley and Dr. Sarah Prince, the time
spent with you proved to be a turning point giving me the jump start and encouragement
needed when I suffered from writers block. I thank all of you for the roles you have
played in helping me reach this point in my academic career.

Table of Contents
List of Tables ..................................................................................................................... iv
List of Figures ......................................................................................................................v
Chapter 1: Introduction to the Study....................................................................................1
Background ....................................................................................................................1
Influenza Microbiology and Clinical Description .................................................. 1
Influenza Epidemiology .......................................................................................... 3
Influenza Statistics and Burden .............................................................................. 4
Influenza Vaccine Use ............................................................................................ 5
Clostridium difficile Microbiology and Clinical Description ................................. 6
Clostridium difficile Epidemiology......................................................................... 7
Clostridium difficile Statistics and Burden ............................................................. 8
Problem Statement .......................................................................................................10
Purpose of the Study ....................................................................................................11
Research Questions and Hypotheses ...........................................................................11
Theoretical Foundation ................................................................................................12
Nature of the Study ......................................................................................................13
Definition of Terms......................................................................................................13
Assumptions and Limitations ......................................................................................16
Assumptions.......................................................................................................... 16
Limitations ............................................................................................................ 16
Scope and Delimitations ..............................................................................................17
i

Significance..................................................................................................................19
Summary ......................................................................................................................20
Chapter 2: Literature Review .............................................................................................21
Introduction ..................................................................................................................21
Research Strategy.........................................................................................................22
Theoretical Foundation ................................................................................................23
Epidemiologic Wheel............................................................................................ 23
Current Trends in Influenza .........................................................................................26
Antibiotic/Antiviral Stewardship .................................................................................30
Antibiotic/Antiviral Stewardship and CDAD ..............................................................31
History and Changing CDI Epidemiology ...................................................................34
CDI Seasonality ...........................................................................................................35
Summary ......................................................................................................................37
Chapter 3: Research Method ..............................................................................................38
Research Design...........................................................................................................38
Population and Sampling .............................................................................................39
Study Population ................................................................................................... 39
Sample Size........................................................................................................... 41
Variable Descriptions...................................................................................................42
Data Analysis Plan .......................................................................................................46
Threats to Validity .......................................................................................................50
Ethical Concerns ..........................................................................................................50
ii

Summary ......................................................................................................................52
Chapter 4: Results ..............................................................................................................53
Data Collection ............................................................................................................54
Results ..........................................................................................................................56
Research Question 1 ............................................................................................. 60
Research Question 2 ............................................................................................. 62
Research Question 3 ............................................................................................. 64
Summary of Results .....................................................................................................66
Chapter 5: Discussion, Conclusions, and Recommendations ............................................68
Interpretation of the Findings.......................................................................................68
Limitations of the Study...............................................................................................73
Recommendations ........................................................................................................74
Implications..................................................................................................................76
Conclusion ...................................................................................................................79
References ..........................................................................................................................80
Appendix A: Figure 1 Usage Permission...........................................................................92
Appendix B: Data Usage Permission.................................................................................95

iii

List of Tables
Table 1. Study Variables ....................................................................................................45
Table 2. Clostridium difficile Positive Sample by Region, Gender, Age and Antimicrobial
Receipt ...................................................................................................................57
Table 3. Frequency for Sampled Gender and Regions and Percent With Clostridium
difficile ..................................................................................................................59
Table 4. Binary Logistic Regression With Antiviral Use Predicting Clostridium difficile
60 Days After Discharge ........................................................................................61
Table 5. Classification Table for Antiviral Use as Examined in Research Question 1 .....62
Table 6. Binary Logistic Regression With Antibiotic Use Predicting Clostridium difficile
60 Days After Discharge ........................................................................................63
Table 7. Classification Table for Antibiotic Use as Examined in Research Question 2 ...64
Table 8. Binary Logistic Regression With Antibiotic and/or Antiviral Use Predicting
Clostridium difficile 60 Days After Discharge ......................................................65
Table 9. Classification Table for use of Antivirals and/or Antibiotics as Examined in
Research Question 3 ..............................................................................................66

iv

List of Figures
Figure 1. Wheel model of man-environment interactions .................................................24

v

1
Chapter 1: Introduction to the Study
Background
The word influenza is derived from the Latin “influentia,” meaning influence of
the stars. This star influence was thought to be the cause of influenza epidemics by
ancient populations (Nelson & Williams, 2007). The Clostridium difficile organism is
difficult to isolate in culture, requiring anaerobic conditions and special culture media,
leading to the name Clostridium difficile (Isada, Kasten, Goldman, & Aberg, 2003).
Individually, the prevalence of influenza and Clostridium difficile represent public health
issues. Therefore, a study opportunity exists to gather insight and determine the details of
the type of relationship between these two organisms.
In Chapter 1, I provide background information and a platform of clinical
descriptive facts about influenza and Clostridium difficile. For the purpose of this study, I
provide evidence of the influenza virus complex structure and epidemiology, the
financial, morbidity, and mortality burden this organism has on society, and the impact
the influenza vaccine plays in prevention. Additionally, Clostridium difficile
microbiology, epidemiology, statistics, burden, and role of antimicrobial stewardship will
be discussed.
Influenza Microbiology and Clinical Description
Influenza is a highly contagious illness caused by the orthomyxoviruses. The
influenza virus is an enveloped, eight-segmented, single-stranded, helical shaped
ribonucleic acid (RNA) virus from the orthomyxovirus family (Orthomyxovirus, 2012).
This virus is classified into three groups: A, B, and C, which are based on antigenic
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differences of internal proteins (Isada et al., 2003). Influenza type A is the most common
form of influenza and is found to attack in epidemic proportions in humans and other
animals. Type B is not as common as A and generally causes outbreaks every 2 to 4
years. Type C is the least common, causing milder forms of sporadic infection. All three
groups of influenza viruses frequently mutate due to the small amount of RNA genetic
material within a virus (Influenza, 2003).
Orthomyxoviruses cause illness when they gain entry into host cells and replicate
within them (Influenza, 2003). The new viruses explode from the host cell and infect
other cells. Orthomyxoviruses are sphere-shaped viruses that contain RNA. The virus’s
RNA is used like a blue-print plan for replication within host cells. The outer envelope of
an orthomyxovirus is studded with protein spikes that aid the virus to invade host cells
(Influenza, 2003). There are two different types of spikes on the virus's outer envelope;
one type is composed of hemagglutinin (H) protein (Influenza, 2003). The H protein
fuses with the host cell membrane and allows the virus particle to enter the cell. The
second type of spike is made of the neuraminidase (N) protein (Influenza, 2003). The N
protein helps the newly formed virus particles to bud out from the host cell membrane
(Influenza, 2003).
In the envelope transmembrane protein spike H, there are three types, and N has
two types. This ability to mutate allows the virus to cause frequent outbreaks. The
mutations occur from the gradual and continuous antigenic changes in the H and N
proteins. Subtle changes, typically in the H protein, are termed “antigenic drift,”
responsible for most seasonal influenza strain changes (Nelson & Williams, 2007).
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Sudden and significant changes in the H and N proteins are termed “antigenic shift” and
are responsible for influenza pandemics (Nelson & Williams, 2007). Strains of influenza
are labeled according to a standard naming convention of the type of internal protein: A,
B, or C; the location where the strain was first identified; strain number from isolating
laboratory; year of isolation; and the virus subtype or H/N type (Nelson & Williams,
2007). Some examples include A/California/7/2009/H1N1 and A/Fujian/411/2002/H3N2
(Nelson & Williams, 2007).
Influenza Epidemiology
Influenza is a highly infectious viral illness and the cause of worldwide
respiratory disease. It is spread person to person by inhalation of aerosolized droplets that
contain the virus and exposure to contaminated fomites (Heymann, 2008). Recurrent
episodes of influenza happen every 1 to 3 years due to “antigenic drift” and have been
observed for over 400 years (Isada et al., 2003). Worldwide pandemics caused by
antigenic shift occur every 10 to 20 years and result in high mortality rates (Isada et al.,
2003). The epidemic or pandemic population response varies in the size and impact due
to the degree of antigenic variation, virulence of the new virus, and the level of protective
immunity of the affected population (Nelson & Williams, 2007). The Centers for Disease
Control and Prevention (CDC) reports, in North America seasonal influenza epidemics
usually occur between November and March each year with peak months typically being
January and February (CDC, 2009). These epidemics are characterized by high attack
rates of 10 to 20% of the population (Nelson & Williams, 2007). The results are
absenteeism among schools and work place, increased visits to healthcare providers,
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increased pneumonia, influenza related hospital admissions, and death from influenza and
influenza complications. Common complications from the flu can include coinfections
with other viral or bacterial organisms, primary viral pneumonia, exacerbation of
underlying medical conditions such as pulmonary and cardiac diseases, secondary
bacterial pneumonia, sinusitis, and otitis media (CDC, 2011). Viral spread during North
American winter months is a result of the influenza virus’s increased survival in lower
temperatures and humid environments. Additionally, indoor crowding caused by weather
may lead to viral spread (Nelson & Williams, 2007).
Influenza Statistics and Burden
Each year, influenza causes approximately 36,000 deaths in the United States and
over 200,000 hospitalizations (CDC, 2007b). Rates of infection are higher in infants and
children than adults, which is often attributed to children being immunologically naïve to
the virus (CDC, 2009). The rates of hospitalization are highest among infants and elderly
(CDC, 2009). The economic impact of the flu is greater than $80 billion annually in the
form of hospital costs, outpatient visits, loss of life, and missed days of work (Klepser &
Hagerman, 2011). Data released from the CDC indicated that influenza vaccination
coverage remains low in adults and children (CDC, 2009). During the 2005 to 2006 flu
season, one in five children ages 6 to 23 months were fully vaccinated, and many other
children who needed to receive the two dose regimen only received one dose (CDC,
2007). Throughout the United States, no state had more than 40% of children fully
vaccinated and significantly fell below the 60% target for high risk people ages 18 to 64
years (CDC, 2007). In age categories for adults in the 2005 to 2006 season, vaccination
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coverage was 30.5% for 18 to 49 year olds in high risk categories, 18.3% in nonhigh risk
of this same age group, 36.6% in adults 50 to 64 years old, and 69.3% in adults who were
65 and older (CDC, 2007c). However, Healthy People 2020 objectives outline to increase
the proportion of children and adults who are vaccinated annually against seasonal
influenza, thereby improving vaccination for all ages (U.S. Department of Health and
Family Services, 2012).
Influenza Vaccine Use
The fall and winter months in the United States are when the influenza virus
causes disease, illness, and death. Each flu season, there are hundreds of thousands of
hospitalizations and deaths due to the virus. Many hospitalizations and death could be
avoided because the use of the influenza vaccination can prevent the infection and its
health complications (CDC, 2010). The vaccine is targeted and recommended for use in
individuals at risk of influenza complications and to reduce the transmission of flu to
others. In particular, the attack rate of the seasonal illness from the flu is of concern
among individuals 65 years and older, in which the death rate from influenza is greatest
(CDC, 2009). The CDC’s Advisory Committee on Immunization Practice (ACIP)
provides the annual recommendations for flu prevention strategy efforts. The ACIP
examines vaccine effectiveness, coverage, supply, safety, and efficacy. The influenza
vaccine must be given annually because the circulating strains change slightly each year,
and the vaccine must be formulated to match what the predicted strains will be. Despite
efforts to improve the number of people who receive a yearly influenza vaccine, vaccine
receipt coverage still remains low. Furthermore, the antigenic diversity of the influenza
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virus complicates efforts to aggressively vaccinate the public, as was seen in the recent
years from the H1N1 circulating strain (Klepser & Hagerman, 2011).
Clostridium difficile Microbiology and Clinical Description
Clostridium difficile, another variable that was considered in this study, is a grampositive, spore forming, anaerobic rod (Isada et al., 2003). It is the most frequent cause of
colitis associated with antibiotic use (Nelson & Williams, 2007). This bacterium can live
in the gut of infant and adult carriers causing no harm, but it can lead to severe diarrheal
disease in susceptible people. Clostridium difficile infection (CDI) commonly causes
diarrhea but has been linked to the more severe disease of pseudomembraneous colitis
and toxic megacolon (Drekonja et al., 2011). Clostridium difficile can produce two
toxins: A and B; these “exotoxins” cause damage to the colon and result in diarrheal
illness (Isada et al., 2003). Certain environmental conditions are required for expression
of the toxigenic process within the intestinal lumen. The more common toxin A is
described by Isada et al. as an “enterotoxin” and B as a “cytopathic” toxin. Most strains
causing diarrheal illness produce both A and B toxin; however, there are cases where
only one of the two toxins is expressed. There are a number of nontoxigenic Clostridium
difficile strains that lack the gene for toxin A and B and do not cause diarrheal illness.
Clostridium difficile toxin production is of clinical importance and relevance to detect by
laboratory methods because the toxins cause inflammation and damage of the intestinal
wall in addition to secretion of fluid into the intestinal lumen that can lead to necrosis of
the colonic mucosa (Farrow et al., 2013; Isada et al., 2003). Garey (2011) described the
hyper-virulent BI/NAP1/027 strain of Clostridium difficile as being associated with an
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increased toxin production and a higher rate of sporulation, resulting in increased
morbidity and mortality in the United States. Therefore, Clostridium difficile can produce
no toxins, low levels of toxins, or be highly toxigenic.
The Clostridium difficile organism can be found in two forms: a vegetative form
and spore form. The vegetative form is sensitive to oxygen and is easily killed in the
environment (Isada et al., 2003). The spore form is hardy and heat stable, allowing it to
survive in even the most inhospitable conditions of gastric acids and endure many
commercial disinfectants (Isada et al., 2003).
Clostridium difficile Epidemiology
Risk factors for acquisition of CDI are exposure to antibiotics, hospitalization,
and advanced age with a decreased immune response (APIC, 2008). CDI is most
commonly associated with exposure to antibiotics and the acquisition of Clostridium
difficile from fecal-oral transmission. Some people will develop CDI and its associated
clinical diseases while others will only be asymptomatic and colonized. According to
APIC, the “pathogenesis” of Clostridium difficile acquisition involves oral ingestion of
spores that resist the acidity of the stomach and germinate into vegetative bacteria in the
small intestines. Exposure to antibiotics alters the normal intestinal flora and provides the
environmental conditions for Clostridium difficile to multiply, thrive, and potentially
produce toxins that cause mucosal damage. Garey (2011) described nearly all antibiotics
have been implicated as the causative agent in the development of CDI. In particular,
broad spectrum antibiotics, antibiotics that eliminate anaerobic flora, and certain
antibiotic classes such as cephalosporins, clindamycin, and flouroquinolones are most
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highly implicated (APIC, 2008; Gerding, 2004). Antibiotics are the cause of the
suppression of normal intestinal flora and this permits the overgrowth of Clostridium
difficile, which can result in high levels of toxins to be produced (Isada, 2003). In
contrast, Isada described when the selective pressure of antibiotics is not present, the
acute infection with Clostridium difficile is self-limited and the person is asymptomatic
afterwards.
“Colonization” with Clostridium difficile can be found in people of all ages and
not be associated with clinical disease. The organism can be cultured from healthy adult
stool 3% to 5%, and among hospitalized adults, 10% to 30% are colonized with this
organism (Isada, 2003). Colonization can occur with toxin-producing strains and
interpretation of stool tests for Clostridium difficile should be correlated with diarrhea
and symptoms (APIC, 2008).
Clostridium difficile Statistics and Burden
The CDC (2012) reported between the years 2000 to 2009 an increase in the
number of patients with CDI in any discharge diagnosis doubling from 139,000 to
336,600 and the number with a primary diagnosis of CDI tripling from 33,000 to
111,000. Additionally, the CDC described Clostridium difficile was associated with
14,000 deaths, with more than 90% in > 65 years of age, and over 335,000 annual
hospitalizations, Garey (2011) reported the cost of CDI ranges from $433 to $797 million
annually. The CDC reported excess healthcare costs of hospital-onset CDI as $5,042 to
$7,179 per case with a national annual estimate exceeding $1 billion dollars (CDC,
2012b). Tabak, Zilberberg, Johannes, Sun, and McDonald (2013) mirrored the
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attributable cost of hospital-onset CDI at $6,117 per case. Additionally, Tabak et al.
discovered patients with hospital-onset CDI lengths of stay were 2.3 days longer and
experienced a statistically significant higher mortality rate of 4.5% for in-hospital
attributable mortality effect compared to endemic setting attributable mortality of 1 to
2%. The CDC has reported Clostridium difficile is no longer just a hospital issue, with
almost 94% of CDI occurring in people who recently received medical care in or out of
the hospital setting. Furthermore, 75% of infections have an onset in nursing home
settings or in people who were recently cared for in an outpatient medical setting (CDC,
2012b).
One aspect of quality health care that can prevent the occurrence of CDI is
antimicrobial stewardship (CDC, 2012b). The CDC reports the risk of CDI development
increases by seven to 10 fold while a patient is taking antibiotics, and this risk persists for
1 month after discontinuation of antibiotics. Additionally, this risk is three fold for the
next 2 months post antibiotics use (CDC, 2012b).
Influenza continues to be unpredictable as new and emerging strains occur,
making the reality that influenza related illness and hospitalizations will continue despite
best efforts to immunize the population. The rates of CDI continue to increase nationally.
Of concern is the impact this disease has on the aging population where the risk factors
for acquisition are more pronounced: exposure to antibiotics, hospitalization, and
advanced age with a decreased immune response. In summary, both influenza and
Clostridium difficile represent a significant impact to patients and heath care providers in
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terms of hospitalization, morbidity, mortality, and economics related to management of
these diseases.
Problem Statement
Annually influenza causes thousands of deaths in the United States and hundreds
of thousands hospitalizations (CDC, 2010). CDI has emerged as the most common cause
of antibiotic-associated diarrhea and a highly problematic healthcare-associated infection
(Garey, 2011). Nearly all antibiotics have been implicated in CDI, with certain
antimicrobial classes causing higher risk for disease (APIC, 2008). Use of antibiotic
agents can vary by season (Gelband, 2009; Linder, Bates, & Platt, 2005). Seasonal
antibiotic use may indicate inappropriate prescribing patterns (Polgreen, Yang, Bohnett,
& Cavanaugh, 2010). CDI does follow a seasonal pattern that peaks in mid-March in the
United States (Jagai et al., 2007). Incidence of CDI may be related to the incidence of
seasonal influenza; however, most of the literature reviewed revealed access limitations
to clinical, microbiologic, and dispensed antibiotic data in the same databases, and no
readily available national data that aggregate the monthly receipt of antibiotic agents in
hospitalized populations (Polgreen et al., 2010). This limitation has made it difficult to
draw conclusions about the role antibiotics may have in the development of CDI during
flu seasons. Therefore, this study addressed a problem of using a database that includes
microbiologic, antibiotic, and antiviral agent use in hospitalized patients. Use of a
database rich in these elements in this study helped improve understanding of the
development of CDI during influenza seasons. The potential for social change exists,
providing additional insight into linking seasonal fluctuations in CDI and influenza
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activity, and further implying reasons to prevent influenza through immunization and
focus appropriate antibiotic/antiviral use during the influenza season.
Purpose of the Study
The purpose of this quantitative study was to examine the temporal progression of
CDI incidence and the possible influence that seasonal variation of influenza and
antibiotic and antiviral use has on the incidence of CDI. An enhanced understanding was
determined about the relationship of CDI and seasonal influenza and the role/influence of
antibiotic use and selection. The study’s significance further contributed to the growing
body of knowledge of the implications that antibiotic use has on CDI. In this study, I
determined if the overuse and/or inappropriate use of antibiotics has an impact on the
development of CDI during seasonal disease outbreaks of influenza.
Research Questions and Hypotheses
This study was guided by the following research questions:
Research Question 1: Is there a relationship between use of prescription antivirals
and CDI within 60 days of discharge in patients who have been hospitalized for
influenza?
H01: There is not a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha1: There is a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
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Research Question 2: Is there a relationship between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza?
H02: There is not a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
Ha2: There is a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
Research Question 3: Does the use of prescription antivirals and/or prescription
antibiotics predict CDI within 60 days of discharge in patients who have been
hospitalized for influenza?
H03: The use of prescription antivirals and/or prescription antibiotics does not
predict CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha3: The use of prescription antivirals and/or prescription antibiotics does predict
CDI within 60 days of discharge in patients who have been hospitalized for influenza.
Theoretical Foundation
The epidemiologic wheel is a model of disease causation that brings together the
outer wheel segments of physical, social, and biological environment factors with two
inner circles, with genetics nested in the host circle (Davis, 2000). The wheel of causation
illustrates there are multiple etiologic factors that interact to cause human infectious
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disease (Peterson, 1995). This model was used as the theoretical foundation for this study
and is discussed further in Chapter 2.
Nature of the Study
A retrospective, observational design was used to describe and analyze the
relationship between the incidence of CDI and the variables of antiviral/antibiotics
among an influenza positive population. The data were abstracted using a convenience
sample from a propietary database. This database receives hospital data feeds of
admission, transfer, and discharge (ADT), laboratory microbiologic, and pharmacy data.
The collected patient data were queried and abstracted for study variables; the
independent variables’ delivery of antiviral/antibiotics as well as the dependent variable
of positive test or diagnosis of CDI among patients with a diagnosis and/or positive test
for influenza was analyzed using multiple logistic regression.
Definition of Terms
The following section provides definitions of terms and phrases that were used to
describe concepts and variables important to this study.
Antibiotic: “A drug that is used to kill harmful bacteria and cure infections”
(Antibiotic, 2013).
Antigenic drift: “The ‘evolutionary’ changes that take place in the molecular
structure of DNA/RNA in microorganisms during their passage from host to another. It
may be due to recombination, deletion, or insertion of genes, to point mutations, or to
several of these events. It leads to alteration in the antigenic composition and thus in the
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immunological responses of individuals and populations to exposure to the
microorganisms concerned” (Porta, 2008, p. 7).
Antigenic shift: “A mutation, or sudden change in the molecular structure of
DNA/RNA, in microorganisms, especially viruses, that produce new strains of
microorganisms. Hosts previously exposed to other strains have little or no acquired
immunity. Antigenic shift is believed to be the explanation for the occurrence of strains
of influenza associated with large-scale epidemics and pandemic spread” (Porta, 2008, p.
7).
Antimicrobial: “Any drug, medication, or agent that acts to destroy bacteria”
(Rothenberg, 1999, p.23).
Antimicrobial stewardship: “Coordinated interventions designed to improve and
measure the appropriate use of antimicrobial agents by promoting the selection of the
optimal antimicrobial drug regimen dosing, duration of therapy, and route of
administration” (Society for Healthcare Epidemiology of America [SHEA], Infectious
Diseases Society of America [IDSA], & Pediatric Infectious Diseases Society [PIDS],
2012, p. 323).
Antiviral: “Opposing a virus, weakening or abolishing its action” (“Antiviral,”
1972, p. 86).
Clostridium difficile: “A gram-positive, spore forming, anaerobic rod which
causes millions of human infections each year, with an increasing incidence in recent
years” (Isada et al., 2003, p. 83).
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Colonization: “Presence of organisms in or on the body site, but not causing
clinical signs or symptoms of infection” (“Colonization,” 2002, p. 69).
Cytopathic: “Pertaining to a diseased condition of a cell” (“Cytopathic,” 1972, p.
319).
Enterotoxin: “A toxin that is produced by microorganisms and causes
gastrointestinal symptoms” (“Enterotoxin,” 2012).
Exotoxin: “A protein produced by a bacterium and released into its environment
causing damage to the host by destroying other cells or disrupting cellular metabolism”
(APIC, 2008, p. 7).
Influenza: “An acute viral disease of the respiratory tract characterized by fever,
cough (usually dry), headache, myalgias, prostration, coryza and sore throat” (Heymann,
2008, p. 315)
Influenza antiviral agent: “Four licensed prescription antiviral agents available in
the United States: amantadine, rimantadine, zanamivir, and oseltamivir” (CDC, 2011, p.
6).
Influenza diagnostic tests: “Diagnostic tests available for influenza include viral
culture, serology, rapid diagnostic (antigen) testing, reverse transcription polymerase
chain reaction (RT-PCR), and immunofluorescence assays” (CDC, 2011, p. 4).
Pathogenesis: “The mechanisms by which a cause or etiological agent produces
disease” (Porta, 2008, p. 181).
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RT-PCR: “Reverse transcription polymerase chain reaction is a method to amplify
small quantities of the nucleic acid of a microorganism so the microorganism can be
detected by other molecular biology means” (Isada et al., 2003, p. 553).
Seasonal variation: “Change in physiologic status or in disease occurrence that
conforms to a regular seasonal pattern” (Porta, 2008, p. 225).
Assumptions and Limitations
Assumptions
In this research, I assumed that the established risk factors for exposure to
antibiotics and antivirals during the influenza season were not significantly different
among the U.S. hospitals in this study. Jarvis et al. (2009) studied hospitalized patients
and found 79% of patients received antibiotics prior to Clostridium difficile associated
disease (CDAD). It is assumed for the purpose of this study that antibiotic/antiviral
consumption will be similar across the hospitals used in the study data set.
Another assumption was the diagnosis data received were based on clinical signs
and symptoms and interpreted laboratory results from qualified healthcare professionals.
Laboratory test results are assumed to be performed using Clinical and Laboratory
Standards Institute standards, qualified laboratory professionals, and FDA approved tests.
While the data were not directly collected by me, it was assumed the data were accurate.
Limitations
The data used in this study were collected for patient care and not for research.
The accuracy for use of these data for the purpose of a research study may have been
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questionable. The study’s retrospective design may have had limits of interpretability
because of the data accuracy.
The study was limited to association of data and would not allow for a cause and
effect inference because I did not directly collect the data. An observational,
nonexperimental design limits the interpretation of the results (McPherson & Bunker,
1991). I used a proprietary database from a set of hospitals that pay for the electronic
surveillance system and pharmacy modules. This willingness to pay for these services
made this group of hospitals unique in terms of their commitment to infection prevention,
data collection, and antimicrobial monitoring. The collected research cohort increased
sampling bias more than that seen in random sampling, while increased internal validity
from the surveillance system’s organized, consistent methodology for isolate and
antimicrobial results data.
Additional limitations include that the patient data were not queried for
documentation of underlying medical conditions that can be exacerbated by influenza
infection, nor were they queried for secondary infections, coinfections, or complications
from influenza. Moreover, documentation or knowledge of influenza vaccine receipt was
not queried in the study population, and the patient’s immune response to the vaccine, if
received, remained unknown.
Scope and Delimitations
Influenza causes thousands of deaths in the United States annually and hundreds
of thousands hospitalizations (CDC, 2010), and CDI has emerged as the most common
cause of antibiotic-associated diarrhea and a highly problematic healthcare-associated
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infection (Garey, 2011). The focus of this study, therefore, was to gather a convenience
sample of information across U.S. hospitals. I used sampling from a group of hospitals
that pay for an electronic surveillance system.
For this study, long term care, rehabilitation, and children’s hospitals were
excluded from sampling. Sampling was from acute care hospitals and adult patients. In
long term hospital and rehabilitation settings, patients are often treated as residents and
have healthcare issues and disease management that are not considered acute. Children’s
hospitals were also excluded, as seasonal respiratory illnesses seen in the very young
during the typical influenza season often manifest as respiratory syncytial virus (RSV)
and other respiratory syndromes (Nelson & Williams, 2007). The CDC reports that
during the influenza season, there are more outpatient visits in children 7 to 12 years old
(CDC, 2010). Furthermore, among children age 5 to 7, there were more antibiotic
prescriptions provided per 100 children than age 15 and younger compared to time
periods when seasonal influenza is not circulating (CDC, 2010). Additionally, annual
hospitalization rates for lab confirmed influenza decrease with increasing age (CDC,
2010). Children are often less exposed to antibiotics in terms of years and the antibiotic
choices selected by pediatricians and neonatologists. Therefore, data for lab confirmed
influenza with inpatient antibiotic utilization among children would be more difficult to
find.
The cohort of hospitals used in the study may not accurately represent all United
States hospitals and, therefore, the resulting delimitation may have decreased the ability
to generalize.
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Significance
Researchers have shown the relationship of risk factors for CDI as exposure to
antibiotics, hospitalization, and advanced age (AHRQ, 2012; APIC, 2008; Garey, 2011;
Jarvis, Schlosser, Jarvis & Chinn, 2009). Little published literature exists supporting the
theoretical aspects of how seasonal variations of influenza incidence and antibiotic use
relate to CDI development in hospitalized patients. Influenza and CDI development
studies have been limited by data sources, including administrative data versus clinical or
microbiologic data (Polgreen, 2010). Furthermore, antibiotic use is an additional factor in
this equation that has not been studied due to lack of readily available, nationwide data
aggregating receipt of antibiotics in hospitalized patients or access to reliable antibiotic
data in individual hospitalized patients (Polgreen, 2010).
There are significant implications for social change. Knowledge from an
epidemiologic study of seasonality of disease and antibiotics can have an influence at
local and organizational levels. Healthcare providers can benefit from recognizing the
affect that antibiotic delivery in hospitals and healthcare settings has through more
informed choices for use and pharmacologic recommendations, in other words, through
increased “antibiotic stewardship”. Jarvis et al. (2009) found the considerable morbidity
and mortality associated with CDI calls for implementation of comprehensive evidencebased Clostridium difficile measures. Antibiotic resistance and CDI are health care issues
that affect the hospitalized patient and can have implications for affecting the general
public once the patient is released from a healthcare setting, such as exposing the
community population and environment to antibiotic resistance and CDI.

20
Summary
The epidemiology of CDI has changed over recent years. The attributable
economic burden to healthcare providers and the added morbidity and mortality to
patients makes this issue a public health concern. Influenza puts the population and
public health into a conundrum every year as the virus shifts and drifts causing challenges
for vaccine producers to provide a good match to the circulating strain. Vaccine receipt is
an important part of reducing the incidence of influenza. The populations most at risk for
complications of the flu are often hospitalized and die due to lack of prevention efforts
such as annual vaccination.
In Chapter 2, a review of the literature will be as analyzed to further describe the
role of influenza, CDI, and antibiotic stewardship. This review is important to provide
further understanding for the readers about the study variables and highlight what is
known and where inconsistencies and gaps exist. From the analysis, a gap in the literature
will be revealed and formulate the need for research. In Chapter 3, methodology, I will
describe how the research was carried out, and I will discuss how the study answers the
research questions and hypotheses. I will also describe the study variables, ethics, and
data handling. Chapters 4 and 5 will outline the study results, discussion of the findings,
and implications for social change. References and any appendices are provided in the
last pages of the document.
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Chapter 2: Literature Review
Introduction
The literature review was performed to gain a thorough understanding of the
epidemiologic research related to Clostridium difficile, influenza, and the concept of
antimicrobial stewardship. In order to comprehend the current models and beliefs of CDI
development, the literature review includes a historic and current perspective of CDI
epidemiology; searches for this literature were performed without date limitations in
multiple databases. This literature search revealed hundreds of articles that were then
narrowed to relevance for this study.
The purpose of the literature review is to effectively discuss the problems
associated with the development of CDI in the United States and reveal a gap in the
literature for the variables of this study. The approach is to organize the literature into a
basic historic and epidemiologic perspective of CDI through the history and
microbiology of Clostridium difficile. The literature review also provides background
information and data to support the problem of variability of physician ordering of
antiviral/antibiotics use overall and during times of influenza incidence. Furthermore, the
literature provides an understanding of the concept of antimicrobial stewardship and
provides supporting literature of antimicrobial use related to the development of CDI. In
the final portion of this chapter, I will discuss the literature related to the variables used in
this study. Also drawn from literature are components of population and setting as a
framework that shaped the study design and methods.
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Research Strategy
The literature search was conducted through multiple databases including
EBSCOhost, MEDLINE, CINAHL Plus, and Cochran Collection Plus (through the
Walden University library). In addition, searches were conducted through Google Scholar
and the CDC website. Finally, the Michigan eLibrary and Ironwood Carnegie Library
were used to search for literature. EBSCOhost MEDLINE full text search for scholarly
peer reviewed journals, years 2000 to 2013 revealed the following: 147 results using the
terms influenza and antibiotics, 113 results using the terms influenza and antivirals, 47
results using the term antibiotic stewardship, and 949 results using the term Clostridium
difficile. ProQuest search of peer reviewed articles, years 2009 to 2013, using terms
influenza and antibiotics, revealed 54 results with one article used. Also searched were
the CDC’s primary peer-reviewed publication, Morbidity and Mortality Weekly Report,
and I used my own peer reviewed journal holdings and subscriptions of the American
Journal of Infection Control and the American Journal of Public Health to search for
articles of relevance. Use of bibliography mining for citation chains was a search strategy
used from key articles that were of close relevance to my research questions. Any
journals or books pertinent to the research were downloaded, purchased, or procured for
use.
A variety of terms were used to search for pertinent literature in the databases
listed. The following common terms were searched: influenza and antibiotics, influenza
and antivirals, Clostridium difficile, Clostridium difficile risk factors, Clostridium
difficile-associated disease, Clostridium difficile infection, antibiotic stewardship,
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history of Clostridium difficile, seasonal influenza, and wheel model. Searches were also
enhanced from article referrals from work colleagues who are pharmacists and have
ready access to pharmacy journals and positions papers on the key subjects of
antimicrobial stewardship, Clostridium difficile, and antibiotic and antiviral use. Faculty
suggestions for articles were also incorporated into the literature review. Periodic
searches have been conducted through the current month and year to ensure any newly
published articles or positions statements of relevance are found for use.
Theoretical Foundation
Epidemiologic Wheel
Mausner and Bahn (1974) described overall that models of disease have multiple
causation. In the medical community, the focus is on the patient with forces and factors
within the patient, the environment, and microorganisms contributing to disease. This has
been depicted as the epidemiologic triangle with the corners of host, agent, and
environment as labels. This model illustrates that a change in any of the components will
ultimately alter the equilibrium of the triangle and increase or decrease the disease
frequency (Mausner & Bahn, 1974). Mausner and Bahn first described the wheel model
(see Figure 1). It is an elaboration of the man-environment concept with the host or man
at the center, and the man has a genetic makeup nested at the core of this host hub that is
surrounded by the environment, which is divided into three sections. These three
sections--biological, social, and physical--can differ in size depending on the specific
disease or problem. Diseases that are hereditary would have a large genetic core, while
those diseases such as smallpox would have a smaller genetic core. The immune status of
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the host in the biologic environment section and social section may change in size when
considering factors such as exposure to the virus, receipt of a preventative vaccine, or
herd immunity. Mausner and Bahn stated that the wheel model “implies a need to
identify multiple etiologic factors of disease without emphasizing the agent of disease”
(p. 35). In addition, “the wheel model does encourage separate delineation of host and
environmental factors” (Mausner & Bahn, 1974, p. 35).

Figure 1. Wheel model of man-environment interactions. From Epidemiology: An
introductory text (p. 36), by J. S. Mausner and A. K. Bahn, 1974, Philadelphia: Saunders.
Copyright 1974 by W. B. Saunders Company. Reprinted with permission.

The use of this theory relates to the study of understanding determinents of CDI,
seasonal influenza, and the role/influence of antibiotic use and selection. The host or man
at the center has the three sections of environment in play at many stages of the disease
development of CDI. The development of influenza can be based on the lack of vaccine
receipt, naïve host, or a vaccine mismatch due to a differing circulating/novel influenza
strain (CDC, 2009). This section weighs heavy in the biological section, as does receipt
of a good strain match of vaccine for influenza prevention. Additionally, there can be
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biological factors of a dose-response relationship in the development of influenza with
the occurrence of influenza based exposure to the associated influenza strain and the
proportion of vaccine match for those who received it (CDC, 2009; Glezen, 2006).
Admission to the hospital or the need to seek medical intervention for influenza is in the
social and biological sections. This can have social constructs of individual, family, or
cultural groups influencing the health seeking behavior and decisions to seek treatment.
The physical environment includes exposure to Clostridium difficile spores in the
physical hospital environment, and the social aspects include if the physician prescribes
antibiotics that may alter the host gut to develop CDI, as well as the host request and
acceptance of antibiotics. The physican’s desire to use antibiotics may be based on the
need to provide comprehensive coverage for all upper and lower respiratory conditons
without a clear etiology, not having or waiting for influenza testing results prior to the
administration of antibiotics for bacterial infections versus antivirals for viral infections
such as influenza, lack of critical thinking, physician’s need to do something for the
patient, or maintaining patient satifaction as they request medications (Bonner, Monroe,
Talley, Klasner, & Kimberlin, 2003; Linder et al., 2006). The social aspects of care for
the host by the medical provider can greatly influence this portion of the wheel.
Peterson (1995) used the wheel model to describe war and disease. The wheel
model was used to detail the complexity of war conditions. This included concentrations
of people and intermixing of populations. Additionally, resources that may be in short
supply, such as basic hygiene and medical care, along with the diversion of food supplies
that lead to conditions of malnutrition and famine. These factors interact to increase the
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rate of infectious disease and may lead to social disintegration. Peterson found this model
to be more encompassing of multiple etiologic factors, which was necessary to fully
explain the relationship between war and disease. Uzoigwe, Khaitsa, and Gibbs (2007)
used the wheel model to describe the multiple etiologic factors that influence irritable
bowel syndrome. They described the interaction of genetic and environmental factors that
can influence the disease process, including infectious agents, diet, drugs, stress, and
social status. The use of the wheel model by Peterson and Uzoigwe et al. provided
examples of use for research questions that involve a complex set of factors. In this study,
the model can also be used to describe the complexity of antivirals and antimicrobials
with the influence of physician ordering and patient factors.
Current Trends in Influenza
Morbidity and mortality from influenza is linked to the underlying status of the
host, and many factors such as age and comorbidities play a significant role in the
acquisition and ultimate presentation of the disease. In the United States, influenza deaths
have increased over the past 25 years with the highest attack rates among children under
age 5 and individuals aged 65 and older (Klepser & Hagerman, 2011, p. 207). Influenzarelated complications and hospitalization are lowest among children (Klepser &
Hagerman, 2011, p. 209). Aggressive vaccination for the seasonal flu can minimize the
impact of health related influenza illness to populations. Glezen (2006) noted mortality
and hospitalization due to influenza has increased despite increasing vaccine coverage to
the most vulnerable populations. Furthermore, the most vulnerable populations are the
least likely to elicit a full immune response to the vaccine. Glezen found in a review of
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the literature on novel strategies for influenza control that indirect effectiveness of the
influenza vaccine could be obtained when children received the live attenuated vaccine
and herd protection was conferred to adults. Herd immunity or herd protection of a group
can occur when a large proportion of individuals from that group are immune or
immunized to an infectious agent, thereby reducing exposure of those susceptible to that
agent (Porta, 2008). Glezen also noted this same concept for herd protection occurred
among Japanese school children where 50% to 85% of the student population was
vaccinated using injectable vaccine. Traditional Japanese families live in
multigenerational households, the conferred herd protection to the elderly in the
household occurred as a result of the school children’s immunization. In contrast, Kelly,
Kromelis, Jordan, Merryman, and Siegle (2012) used a novel strategy to deliver the
influenza vaccine to primarily adult household contacts of infants aged less than 60
months to increase vaccine uptake among household contacts and reduce household
influenza transmission. The importance of this strategy illustrated it may be the only
means to protect the very young as no influenza vaccine is available for infants aged less
than 6 months. The CDC (2009) statistics indicated that serious illness and death are
highest among children less than 2 years old and adults aged 65 years and older; adults
aged 85 years and older are at the highest risk for death, with approximately 36,000
deaths between 1990 to 1999 and 226,000 hospitalizations from 1979 to 2001.
Symptoms associated with the flu typically emerge abruptly after an incubation
period of 1 to 4 days, and symptoms resolve in 3to 7 days in uncomplicated cases, even
though cough and malaise may last for a few weeks longer (Heymann, 2008). In adults,
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the symptoms are cough, fever, respiratory symptoms, malaise, myalgias, sore throat, and
rhinitis. Children may present with these symptoms and also may exhibit nausea,
vomiting, and otitis media (Heymann, 2008). Because these respiratory symptoms are
often clinically indistinguishable from other respiratory syndromes and viruses, accurate
diagnosis and laboratory confirmation is critical for appropriate treatment choices to
occur. Diagnosis is complicated by the varied and often nonspecific signs and symptoms
of influenza. The primary methods used for diagnosis of influenza infection are viral
culture, rapid diagnostic tests, reverse transcriptase-polymerase chain reactions, or
clinical diagnosis without the laboratory testing based on sign and symptoms and current
statistics of the influenza burden in the population for the time period. Each method has
varied accuracy to predict the presence of the influenza virus; test sensitivity, specificity,
and positive and negative predictive values, therefore, require careful data interpretation
by qualified healthcare professionals. Point-of-care rapid testing can aid in the speed of
diagnosing influenza and can assist clinical decision making for appropriate therapy and
control measures (Heymann, 2008).
Falsey, Murata, and Walsh (2007) studied the impact of rapid diagnosis testing
and the management of adults who were hospitalized with influenza. A review of medical
records over four flu seasons revealed rapid influenza testing leads to reduced antibiotic
use in hospitalized patients. The results of this study found the positive influenza test was
associated with modest withholding or discontinuing antibiotics; however, a significant
portion of the test positive patients at low risk for bacterial infection continued to receive
antibiotics. Physicians were surveyed to assess the beliefs of being comfortable to

29
discontinue antibiotics in patients with negative chest x-rays and negative bacterial
cultures, and two thirds of the respondents believed they would be (Falsey et al., 2007).
Medical record review, however, found in practice that these physicians did not
discontinue antibiotic use (Falsey et al., 2007). Physicians are concerned about secondary
bacterial infections with an influenza diagnosis and the ability to distinguish concomitant
bacterial or viral infections during peak seasons for respiratory illness (Falsey et al.,
2007). Even with sound medical evidence of no secondary or concomitant respiratory
illness or disease, practitioners justified their choice to continue antibiotic use.
Several studies have shown that diagnosis and treatment of influenza is not
consistent among physicians. Linder et al. (2005) found that physicians prescribed
inappropriate antibiotics to 26% of patients, and physicians prescribed antiviral
medication to 19% of patients with an influenza diagnosis. This was similar to results
from a study by Bonner et al. (2003) on decision making in a pediatric emergency room
based on influenza testing information. This study found emergency room physicians,
when blinded to the rapid influenza testing result, were more likely to perform more
blood counts, blood cultures, urinalysis and cultures, and chest x-rays, prescribe
antibiotics, and have patients stay longer in the emergency room with all the associated
costs to the patient. In contrast, emergency room physicians who were aware of the
positive influenza test result used less laboratory tests, antibiotics, and emergency room
time in addition to prescribing antiviral medications more than those physicians who did
not know the influenza test result. The findings of this study provided evidence that
physicians can alter their clinical decisions and patient management in a pediatric
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emergency room setting when they are made aware of influenza rapid testing results prior
to seeing the patient for evaluation. This type of clinical management is the focal point of
antimicrobial stewardship, which involves improving clinical outcomes while minimizing
antibiotic use and its unintended adverse consequences.
Antibiotic/Antiviral Stewardship
Antimicrobial stewardship is defined as “coordinated interventions designed to
improve and measure the appropriate use of antimicrobial agents by promoting the
selection of the optimal antimicrobial drug regimen dosing, duration of therapy, and route
of administration” (SHEA, IDSA, & PIDS, 2012, p. 323).
Bartlett (2011) noted CDI and the crisis of antimicrobial resistance as two major
health care challenges and one of the most pressing public health issues. At the heart of
both of these two challenges is antimicrobial use and abuse (Bartlett, 2011). The CDC
(2012b) noted that “good antibiotic stewardship is an important aspect of quality
healthcare that prevents CDI” (p. 3). Inappropriate antimicrobial use can diminish the
therapeutic benefit of the drug and facilitate the development of drug resistance (Moody
et al., 2012). Antibiotic use is a major contributor to the spread of antimicrobial
resistance, and broad-spectrum antibiotics can lead to diarrhea. “Clostridium difficile is
the most common cause of antibiotic-associated diarrhea” (Olivo & Ranalli, 2013, p32).
Hicks, Taylor, and Hunkler (2013) found among United States outpatients in 2010, 258
million antibiotic prescriptions were written, 8.33 per 1,000 Americans or five antibiotic
prescriptions for every six people. Abbett et al. (2009) discovered the initiation of
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antimicrobial stewardship programs are complex. There are multiple points of care by
healthcare workers and often require difficult behavior changes.
An appropriate choice to treat influenza is antiviral medications. They can reduce
the duration of influenza symptoms by one to almost three days and reduce complications
that require the use of antibiotics (Linder et al., 2005). Additionally, antiviral use may
decrease hospitalization and mortality. Linder et al. found the use of antiviral medications
for management of influenza important, given influenza vaccine receipt and effectiveness
can vary. The CDC states “antiviral medications are an adjunct to influenza vaccination
and are effective when administered as treatment and when used for chemoprophylaxis
after exposure to the influenza virus” (CDC, 2009, p. 2). The primary goal of
antimicrobial stewardship is to improve clinical patient outcomes and minimize
unintended adverse consequences due to inappropriate selection, dosing, and duration of
these medication therapies.
Antibiotic/Antiviral Stewardship and CDAD
The incidence of CDAD before and after implementing antibiotic stewardship
programs has been described by many studies across the United States and other
countries, with similar results. The removal or reducing the use of an offending
antimicrobial agent can result in decreased CDAD. The stewardship protocol of requiring
infectious disease physician or pharmacist approval for prescriptions for most parenteral
antibiotics brought about a significant and lasting reduction in CDAD incidence; a 47%
decrease in all CDAD and 42% decrease in new cases in a hospital setting (Nuila, Cadle,
Logan, & Musher, 2008). Gerding (2004) interpreted epidemiologic evidence that related
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attributable risks for CDAD may be due to the antimicrobial selected and overall
frequency and of use in the population. This was more specifically found in a study by
Gaynes et al. (2004) in a long term care (LTC) setting where two different but similar
fluoroquinolones (gatifloxacin and levofloxacin) were used. The findings by Gaynes et
al. described the use of gatifloxacin and clindamycin were associated with increased risk
of CDAD, and in particular the increased number of days receiving gatifloxacin therapy;
67% of the study patients with CDAD received gatifloxacin compared to 24% who
received clindamycin. Increasing the duration of therapy of gatifloxacin significantly
increased the attack rate and risk for CDAD. Clindamycin has historically been the
second most frequently associated antimicrobial agent associated with CDAD (APIC,
2013; Gerding, 2004). A cost saving measure, formulary change, from levofloxacin to
gatifloxacin had indeed coincided with an increase of CDAD among LTC residents, but
when the gatifloxacin was substituted back to levofloxacin the rate of CDAD decreased
(Gaynes et al., 2004). Similarly, Pear, Williamson, Bettin, Gerding, and Galgiana (1994)
found the increased use and duration of clindamycin use was statistically associated with
and epidemic strain of clindamycin resistant Clostridium difficile and by restricting
clindamycin use, the associated epidemic pattern of CDI resolved, and there was a
marked decreased in new cases of Clostridium difficile. In a contradicting case, Berild, et
al. (2003) compared two similar hospitals in Norway for CDI in terms of antibiotic use
and infection control practices. The researchers obtained point prevalence data of
antibiotic associated diarrhea and antibiotic use from both facilities. Despite the
decreased use of antibiotics in the one hospital, a higher reported incidence of CDI was
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reported. Interestingly, the study could lead the reader to surmise the decreased antibiotic
use did not have an effect on CDI. The study data revealed there was a higher frequency
of Clostridium difficile testing at this hospital, which consequently resulted in a higher
reported incidence of CDI. The results of this study are confounding and may not actually
correlate hospital antibiotic use and the reflected incidence of CDI, but an artifact of
varied laboratory testing and reporting.
The role of antibiotic induced Clostridium difficile diarrhea, infection, and colitis
has been well documented, while the discrete use antivirals in the development of CDI
has not. Colarian (1988) reported a case of Clostridium difficile colitis in a male patient,
with a history of acquired immunodeficiency syndrome (AIDS), who had been treated
with the antivirals acyclovir and azidothymidine (AZT), and had not received any
antibiotics in the prior six months. A group of Clostridium difficile studies where the
patients’ immune systems were compromised revealed use of antivirals, but did not
specify antiviral use individually in the data analysis (Gellad et al., 2007; Gorschlüter et
al., 200; Pulvirenti et al., 2002). In the study by Pulvirenti et al., antimicrobials-- defined
as antivirals, antifungal, and antibacterial agents-- were studied for development of CDI
in human immunodeficiency virus (HIV) patients. The study did not provide detailed
names of the antivirals included nor did it analyze the use of antivirals as an individual
variable. Gellad et al. studied the severity of CDAD in solid organ transplant patients and
specified exposure to antivirals as a variable; the study did not find any statistically
significant differences in development of severe colitis among the study groups of
transplant and non-transplant patients with CDAD. The study did include antivirals as a
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characteristic variable, but did not analyze antiviral use individually. This was also noted
in a study by Gorschlüter et al., where the specific oral antiviral, acyclovir, was used
among study patients. Antiviral class use was an aspect considered in a specific, large
outbreak study by Muto et al., (2005), but was not independently associated with CDI.
Antimicrobial-induced diarrhea and development of CDI are serious
complications of patient medical management and requires thoughtful antimicrobial
selection in the choice to treat any infecting pathogen.
History and Changing CDI Epidemiology
Bartlett (2011) reviewed the 30 year history of CDI and indicated in the late
1970s, antibiotic-associated colitis could occur from almost any antibiotic with an
antibacterial spectrum of activity, but primary offenders were clindamycin and broadspectrum antibiotics. Cephalosporins, clindamycin, and fluoroquinolones have a higher
risk for causing disease due to the antibiotic’s ability to disrupt lower intestine normal
flora (APIC, 2013). Bartlett noted for the first 25of the 30 year time period, CDI was a
severe complication of antibiotic use that could be life threatening, but the mortality rates
were low. Bartlett, 2011; Elixhauser and Jhung, 2008 reported a surge of CDI cases
during the years 2001 to 2005. Not only was there a 102% increase in four years, but also
a substantial increase in attributable mortality. Noticing among the increase in CDAD
deaths and that 80% of these deaths occur in acute care hospital settings, Zilberberg,
Shorr, and Kollef (2008) further found there was an increase in CDAD hospitalizations
for the years 2000 to 2005. This surge in the number of cases and increased mortality has
retrospectively been associated with the new strain of Clostridium difficile, the NAP1
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strain (Bartlett, 2011). The emergence of this strain has been thought to be due to the
developed resistance of Clostridium difficile to fluoroquinolones which had been widely
used, as the NAP1 strain was uncommon in historic strains (Bartlett, 2011). The NAP1
strain hallmark is higher toxin production, which may account for the increase in severity
of outcomes and mortality. Concurrent with this hyper-virulent epidemic strain, fully
identified as BI/NAP1/027, CDI prevalence more than doubled in hospitalized patients
(Tabak et al., 2013). The highest rates of CDI occurred among persons 65 years and
older, with over two-thirds of the patients with CDI being elderly (APIC, 2013;
Elixhauser & Jhung, 2008). Females had higher rates of CDI related hospital stays than
males, and new populations previously thought to be low risk have emerged: healthy
peripartum women, children and healthy adults with minimal or no recent exposure to
healthcare settings (APIC, 2013). An additional change in CDI epidemiology has been
noted in the regional incidence from review of U.S. hospital discharge data. Elixhauser
and Jhung (2008) found “the Northeastern rate was two times higher than the West,
which had the lowest rate. The rates in the Midwest and South were 69 percent and 42
percent higher than the Western rate, respectively” (p. 2). The purpose of this quantitative
study was to examine the temporal progression of CDI incidence and take into account
meaningful data elements, such as geographic regional differences.
CDI Seasonality
Seasonal patterns for CDI have been noted by Jagai et al. (2007), in the United
States a pattern that peaks in mid-March for all age groups. In addition, Polgreen et al.
(2010) found seasonal influenza activity peaked in January and February with CDI peaks
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occurring in March. In contrast, Bruckhardt, Friedrich, Beier, and Eckmanns (2008)
found trends of CDI did not follow obvious seasonal trends like other enteric diseases
such as Salmonella species, Rotavirus, and Norovirus, rather an overall increase in CDI
incidence. In another case, a study conducted by Larang, Repayo, Chan and Murillo
(2011) described Clostridium difficile testing for the year of 2009 and found a bimodal
distribution for ages 71 to 75 and 1 to 5 years, along with a bimodal seasonal distribution
of positive tests that peaked in March and November. R. S. Larang clarified that this
Clostridium difficile study did not consider the influenza season, but indicated it was
interesting the age groups in the study are the same as those most affected by influenza
(personal communication, July 18, 2011). The significance of this study is the data year
used was 2009, this was the year of the novel influenza A (H1N1) that showed very
unique activity and distinct bimodal peaks of influenza activity, in contrast to the typical
seasonal influenza single peak in late fall/early winter in the United States. The
2008/2009 seasonal influenza peak was January 2008 through March 2009, with the
second novel influenza A (H1N1) activity starting and peaking quickly in late April to
early May 2009. The influenza A (H1N1) activity continued through June 2009. The A
(H1N1) strain co-circulated, and in many U.S. regions it never completely diminished
when the seasonal influenza again emerged in September lasting through late December
2009 (CDC, 2012a). Accordingly, Polgreen et al. (2010) found using time-series
methodology while reviewing regional and national level data revealed peak CDI
incidence occurred during or after monthly influenza peaks. The use of time series
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analysis performed for the study implied the seasonal variation was included because the
typical influenza season occurs within each year and recurs periodically year after year.
Summary
The literature review I presented in this chapter provided some historic and
epidemiologic background information of influenza and CDI. Additionally, the concept
of antimicrobial stewardship and the factors driving the need for this strategy where
identified. The literature offered evidence of the well known, key risk factor of antibiotic
exposure contributing the development of CDAD. Also, the literature revealed the key
population characteristics that was used to select my study sample population.
Moreover, the literature provided insight to the dependent and independent
variables. The study basis to suspect that seasonal influenza may be linked to an increase
in the subsequent development of CDI was revealed in the literature. However, lacking in
the literature are studies to analyze aggregate data and support an influenza and CDI link
due to monthly receipt of antibiotics/antivirals in hospitalized patients. The literature
reviewed does provide justification to test the proposed hypotheses and analyze the
association of the independent variables and the one dependent variable using multiple
logistic regression. In Chapter 3, I will describe the research method and design. Also, the
study variables will be discussed and the context of the intended data elements to be
collected will be clarified.
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Chapter 3: Research Method
The purpose of this study is to address the use of antiviral/antibiotic usage during
the influenza season and the incidence of CDI. In this chapter, I discuss the testing of the
hypotheses that explain an association between the use of prescription antivirals or
antibiotics to predict CDI within 60 days of discharge in patients who have been
hospitalized for influenza. A retrospective, observational design was used to describe and
analyze the relationship between the incidence of CDI development and the related
variables of antiviral/antibiotics among patients hospitalized for influenza. The chapter is
divided into sections of research design, population and setting samples, variable
descriptions, data analysis plan, threats to validity, and ethical concerns.
Research Design
In this study, I describe and analyze retrospective observations of data from a
proprietary, laboratory, and pharmacy based system from a cohort of hospitals. The
retrospective nature of this research was chosen based on the timing of the influenza
seasons for the study years. This observational study provides information to explore the
cause of CDI incidence and determinants.
A retrospective observational cohort design was chosen due to the novelty of the
relationship between the variables that had not previously been documented in the
literature reviewed. It seemed reasonable to begin the study inquiry using an
observational study approach. The benefits of using this type of observational study
include a simpler design with the efficiency and ease of collecting retrospective data
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using fewer resources compared to a logistically challenging prospective experimental
design (McPherson & Bunker, 1991).
The limitation of using a retrospective cohort study compared to a prospective
experimental study is detailed information on exposure and confounders may not be
controlled for in the data collection process (Aschengrau & Seage, 2003). Despite this
recognized limitation, the observational design was used for the novel hypotheses with
the rationale the study may not require the resources for an experimental design.
An observational design was chosen over a cross-sectional design due to crosssectional observations are based on a single point in time (Babbie, 2007). The influenza
and development of Clostridium difficile data in this study lends itself to the time-related
option of observations over a longer period of time. The best way to study changes over
time is to utilize a longitudinal study (Babbie, 2007). Therefore, this retrospective cohort
study was based on data collected over the influenza seasons time frame.
Population and Sampling
Study Population
The study population for this research consisted of U.S. hospitals that subscribe to
the surveillance and pharmacy system known as MedMined Surveillance Advisor, a
division of CareFusion (CareFusion, 2013). There are approximately 400 hospitals that
subscribe to the MedMined electronic surveillance module and about 30%, representing
approximately 125 hospitals, subscribe to the electronic pharmacy module known as
Patient Event Advisor. Hospitals that use MedMined have a business agreement for the
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services and pay a monthly fee. The hospital demographic using MedMined services are
primarily short-term acute care hospitals across the United States.
For this study, long term care, rehabilitation, and children’s hospitals were
excluded from sampling. Sampling was from acute care hospitals and adult patients. In
long term hospital and rehabilitation settings, patients are often treated as residents and
have healthcare issues and disease management that are not considered acute. A
convenience sample was used taking into account that the highest rates of CDI occur
among persons 65 years and older, with over two-thirds of the patients with CDI being
elderly, and females having higher rates of CDI related hospital stays than males (APIC,
2013; Elixhauser & Jhung, 2008). It was noted in Chapter 2 that new populations
previously thought to be low risk populations for CDI have emerged: healthy peripartum
women, children, and healthy adults with minimal or no recent exposure to healthcare
settings (APIC, 2013). Healthy, peripartum women and healthy adults with minimal or no
recent exposure to healthcare settings were not excluded. For this study, children were
excluded because the respiratory syndromes seen in the very young during the typical
seasonal influenza season often manifest as RSV (Nelson & Williams, 2007). The CDC
(2010) reported that during the influenza season, there are more outpatient visits in
children and annual hospitalization rates for lab confirmed influenza decrease with
increasing age. Additionally, children are often less exposed to antibiotics in terms of
years and the antibiotic choices selected by pediatricians and neonatologists. Therefore,
data for lab confirmed influenza with inpatient antibiotic utilization among children
would be more difficult to find in this secondary data source (CDC, 2010).
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The changes in CDI epidemiology noted in the regional incidence from a review
of U.S. hospital discharge data was taken into account by sampling more in the
Northeast, Midwest, and South than the Western portion of the United States (Elixhauser
& Jhung, 2008). The United States is divided into four main regions by the U.S. Census
Bureau for population survey and registration data. These four regions are designated by
the Census Bureau as Northeast, Midwest, South, and West and were used for this study
data collection (U.S. Department of Commerce, 2013).
The exact peak and year of seasonality incidence was determined using CDC’s
FluView tracking system (CDC, 2012a). Additionally, seasonal incidence was viewed in
the MedMined graphing feature for each hospital’s source specific data. The graphing
feature allows for visualization of the epidemiologic curve based on the frequency of
positive microbiologic isolates for influenza with the axis’ of number of isolates and
calendar week. Based on this graph, the peak weeks of the season can easily be identified
and further verified with the CDC FluView system of reports geographic incidence
density. This provided time series analysis and insight to seasonal variation.
Sample Size
In order to estimate the minimum sample size required to confidently accept the
results of the analysis, sample size tables for logistic regression were consulted (Hsieh,
1989). The literature indicated the probability of a CDAD diagnosis within 60 days of
hospitalization is approximately 12 (Rodemann, Dubberke, Reske, Seo, & Stone, 2007).
To detect an odds ratio of 2.0 for an individual diagnosed with CDI, one standard
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deviation above the mean using a one-tailed test with a significance of 0.5 and a power of
80%, a minimum of 146 participants was needed (Hseih, 1989).
Variable Descriptions
For this study, the measures collected from each hospital and analyzed for
possible association included the of diagnosis and/or positive test for influenza and the
independent variables of delivery of antiviral/antibiotics during the patient’s
hospitalization as well as the dependent variable of positive test or diagnosis of CDI. In
this study, I used all eligible adult and elderly patients with the operational definition of
adult, 18 to 64 years old, and elderly defined as age 65 years and older. This definition
was consistent for age groups used and defined in the Healthy People 2020 objectives for
improving health (U.S. Department of Health and Human Services, 2020).
The dependent variable of a diagnosis of CDI is defined as a positive laboratory
test for Clostridium difficile using standard laboratory methodology such as, toxin assay,
polymerase chain reaction (PCR), or antigen tests. The definition of CDI included the
diagnosis field listing terms CDI, Clostridium difficile infection, or Clostridium difficile.
The study population was pulled from hospitalized patients with influenza. The
definition of influenza included the diagnosis field listing terms of influenza, flu, and any
flu specific types such as influenza A, B, and H1N1. The diagnosis of influenza is also
defined as a positive laboratory test for influenza using standard laboratory methodology
such as viral culture, serology, rapid diagnostic (antigen) testing, reverse transcription
polymerase chain reaction (RT-PCR), and immunofluorescence assays (CDC, 2011).
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For this study, the antimicrobial independent variables were use of antibiotics and
antivirals among the patient population. Garey (2011) described that nearly all antibiotics
have been implicated as the causative agent in the development of CDI. Broad spectrum
antibiotics and certain antibiotic classes such as cephalosporins, clindamycin, and
fluoroquinolones are most highly implicated (Bartlett, 2011). Therefore, based on the
literature, data extraction to determine if antimicrobials were used was performed, and
use of any antimicrobial without categorization was included for this variable definition
(Bartlett, 2001; Garey, 2011). Several studies provided insight that physicians often
prescribe antibiotics along with antivirals to treat influenza (Bonner et al., 2003; Falsey et
al., 2007; Linder et al., 2005). In particular, among adult patients, Linder et al. found 26%
of patients diagnosed with flu were prescribed antibiotics not associated with an
antibiotic appropriate diagnosis, meaning excluded people whose diagnosis could
credibly include a bacterial infection where antibiotic therapy is appropriate treatment. To
illustrate the impact, Linder et al. found between 2 and 4 million people seek medical
care for the flu every year, and this calculates into 500,000 to 1 million inappropriate
antibiotic prescriptions. Bacterial complication rates from the flu among older adults have
not been studied fully and there lacks data to support antibiotic use as a method of
preventing influenza related complications (Bonner et al., 2003). Additionally, studies
have shown that diagnosis and treatment of influenza is not consistent among physicians
(Bonner et al., 2003; Linder et al., 2005).
In the United States, there are currently four licensed prescription antiviral agents
used to treat influenza: amantadine, rimantadine, zanamivir, and oseltamivir (CDC,
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2011). For this study, the use of any antiviral, including the four antiviral agents used to
treat influenza, was included for this independent variable.
The study population was hospitalized patients with influenza. The definition of
influenza included the diagnosis field listing influenza terminology and/or a positive
laboratory test for influenza. Within this population, the dichotomous dependent (CDI)
and independent variables (antibiotics use, antiviral use, antiviral and/or antibiotic use)
were each coded for value of Yes =1 and No = 0. Table 1 lists the study variables.
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Table 1
Study Variables
Variable type

Name

Definition

Dependent

Clostridium
difficile
infection

Independent

Antibiotic

Positive laboratory
test for Clostridium
difficile using
standard laboratory
methodology such
as, toxin assay,
polymerase chain
reaction (PCR) or
antigen tests.
Definition of CDI
include the
diagnosis field
listing terms CDI,
Clostridium
difficile infection,
or Clostridium
difficile.
Use of any
antibiotic without
class categorization

Independent

Antiviral

Independent

Antiviral
and/or
Antibiotic

Use of any
antiviral, including
the four antiviral
agents used to treat
influenza
Use of any
antibiotic without
class categorization
and/or use of any
antiviral

Coded value
Yes
1 = Meets
definition
criteria

1 = Antibiotic
given, meets
definition
criteria

Coded value
No
0 = Does not
meet definition
criteria

0 = Antibiotic
not given, does
not meet
definition
criteria
1 = Antiviral
0 = Antiviral
given, meets
not given, does
definition
not meet
criteria
definition
criteria
1 = Either
0 = Neither
antibiotic,
antibiotic nor
antiviral, or
antiviral given,
both given,
does not meet
meets definition definition
criteria
criteria
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Data Analysis Plan
The data were from a cohort of hospitals that use CareFusion MedMined services.
In this study, I used proprietary surveillance data that includes patient level information
such as diagnostic laboratory test results, ADT, and prescribed medications such as
antimicrobials and antivirals. Microbiology data for the dependent outcome variable of
Clostridium difficile or diagnosis of CDI and the independent variables of
antibiotics/antivirals use among patients hospitalized with a positive test or diagnosis for
influenza was analyzed using SPSS (Version 22.0). The web based tool owned within
CareFusion MedMined to perform such a query is the Virtual Surveillance Interface
(VSI). The VSI allows the end user to perform specific data extraction by creating
customized, specific reports based on search criteria such as influenza and Clostridium
difficile and inpatient versus outpatient criteria. For this study, a report was written and
used to query based on these organisms and inpatient categorization. The patients
identified from this inquiry were then be further queried for diagnosis details and
medication delivery.
These patient data were queried and abstracted by looking up the indvidual patient
level details using the patient name or medical record number (MRN) and searching the
patient gender, date of birth, and diagnosis data field for a diagnosis of influenza, and
CDI. For the independent variables of delivery of antiviral/antibiotics, a patient level
inquiry was performed from the Patient Event Advisor portion of the MedMined
surveillance system. This was performed using the patient name or MRN search
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functions and running a query for the associated hospitalization admission time frame and
the prescribed antiviral/antibiotics given.
After the data were collected, they were exported and populated into a
spreadsheet to categorize the data elements and details. To protect the identity of the
patient name and identifiable MRN, a new spreadsheet was created and random numbers
assigned. This random number assignment allowed from this point forward to represent
each study subject. From this spreadsheet, the variables were coded and formatted in
preparation for the data analysis.
Before proceeding, a test of the assumptions of the multivariate analysis was
performed. Logistic regression was used to answer both the association and prediction
hypotheses and research questions. Multivariate analysis was performed using logistic
regression to test the hypotheses and determine whether or not the use of
antiviral/antibitotics is associated and predictive of CDI among hospitalized influenza
positive patients. For the first two hypotheses, each independent variable was tested
individually to determine statistical significance.
Research Question 1: Is there a relationship between use of prescription antivirals
and CDI within 60 days of discharge in patients who have been hospitalized for
influenza?
H01: There is not a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
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Ha1: There is a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
The first hypothesis of there is not a statistically significant association between
use of prescription antivirals and CDI within 60 days of discharge in patients who have
been hospitalized for influenza was tested using logistic regression. The dependent
outcome variable of Clostridium difficile or diagnosis of CDI and the independent
variable of antiviral use among patients hospitalized with positive test or diagnosis for
influenza. A p value of 0.05 was used to determine significance. If the results yeild a p
value less than 0.05, the null hypothesis was rejected and the alternative hypothesis was
accepted.
Research Question 2: Is there a relationship between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza?
H02: There is not a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
Ha2: There is a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
The second hypothesis of there is not a statistically significant association
between use of prescription antibiotics and CDI within 60 days of discharge in patients
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who have been hospitalized for influenza was tested using logistic regression. The
dependent outcome variable of Clostridium difficile or diagnosis of CDI and the
independent variable of antibiotic use among patients hospitalized with positive test or
diagnosis for influenza. A p value of 0.05 was used to determine significance. If the
results yeild a p value less than 0.05, the null hypothesis was rejected and the alternative
hypothesis was accepted.
Research Question 3: Does the use of prescription antivirals and/or prescription
antibiotics predict CDI within 60 days of discharge in patients who have been
hospitalized for influenza?
H03: The use of prescription antivirals and/or prescription antibiotics does not
predict CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha3: The use of prescription antivirals and/or prescription antibiotics does predict
CDI within 60 days of discharge in patients who have been hospitalized for influenza.
The third hypothesis was tested using multiple logistic regression analysis. The
use of prescription antivirals and/or prescription antibiotics does not predict CDI within
60 days of discharge in patients who have been hospitalized for influenza. The dependent
outcome variable of Clostridium difficile or diagnosis of CDI and the independent
variables are antibiotics and/or antivirals use among patients hospitalized with positive
test or diagnosis for influenza. The independent variables of either antibiotics, antivirals,
or both were used in the regression analysis for the third hypothesis. Coefficient size and
associated p values for the independent variables was interpreted. If the interpretation is
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not predictive of CDI then the null hypothesis was rejected. The positive or negative
value of each coefficient was analyzed to determine acceptance of the alternative
hypothesis.
Threats to Validity
The potential threat to internal validity that may arise from this study could occur
in the sample selection. Study subjects could have medical or physical characteristics that
may predispose them to certain outcomes or being more susceptible to disease. This type
of detailed data is not in the proprietary data base; therefore, I was unaware of these
details. To account for this threat, use of random selection will increase the probability
that these characteristics will be evenly distributed in the patient study subjects selected
(Creswell, 2009). A potential threat to external validity is the sample population being
only selected from hospitals who subscribe to use of CareFusion MedMined services.
Because this data set only contains a fraction of the all U.S. hospitals, I may not be able
to generalize the results to patient populations in other hospitals. To account for this
threat, research findings will have to restrict claims about other hospitalized patient
populations which the results cannot be generalized.
Ethical Concerns
This study, I did not use human participants directly, but used individual health
information from hospitalized patients with all personal identifiers removed. Data
confidentiality has been described above using a random number system after data
extraction. Protection of the raw data that contains patient names and medical records
with diagnosis and laboratory testing results will be maintained in a locked office during
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the research time period. No personal identifiable information will be reported in the
research study, aggregate data will be reported. After the study is complete and the
dissertation does not require further data review the data will be moved to a locked safe
and maintained for five years before being shredded and destroyed. Data access will be
limited to only me and my committee members, if deemed necessary for dissertation
review and guidance. Procedures for data collection and handling were in accordance to
the Walden University Institutional Review Board (IRB). The IRB application for study
approval reference number is 02-10-14-0119262.
The hospital patient level data within the study population has a business
agreement that includes health insurance portability and accountability act (HIPAA)
language for protection of the data that use MedMined services as a computerized
healthcare vendor. The business agreement allows CareFusion MedMined Services to use
de-identified data for publications and marketing purposes both internal and external to
the company. For the purpose of this study and research access to the data related to the
hospitals and individual patients contained therein will require authorization by
CareFusion MedMined Services. (Appendix B)
The study was carried out using secondary data from CareFusion MedMined
Services and therefore access will be from a remote work environment. The office used
for work is the same office used for research, just with different workstations and
computers. This is a locked office with limited access. Working with CareFusion
MedMined Services database involves using detailed confidential data and the work
environment is set up to be conducive for maintaining confidentiality.
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Summary
I used a retrospective, observational design to describe and analyze the
relationship between the incidence of CDI development and the related variables of
antiviral/antibiotics among patients hospitalized for influenza. The purpose of this study
was to address the use of antiviral/antibiotic usage during the influenza season and the
incidence of CDI using a proprietary laboratory based surveillance system of secondary
data from a cohort of U.S. hospitals.
The data collected was used to test the hypotheses that explains a statistically
significant association between use of prescription antivirals or antibiotics to predict CDI
within 60 days of discharge in patients who have been hospitalized for influenza. The
hypotheses were tested and analyzed using multiple logistic regressions. A detailed
description of the actual analysis and results is presented in the next chapter.
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Chapter 4: Results
The purpose of this study was to examine the use of antiviral/antibiotic usage
during the influenza season and the incidence of CDI among hospitalized patients using a
proprietary laboratory based surveillance system of secondary data from a cohort of U.S.
hospitals. Three research questions with the according hypotheses were explored:
Is there a relationship between use of prescription antivirals and CDI within 60
days of discharge in patients who have been hospitalized for influenza?
H01: There is not a statistically significant association between use of
prescription antivirals and CDI within 60 days of discharge in patients who have been
hospitalized for influenza.
Ha1: There is a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Is there a relationship between use of prescription antibiotics and CDI within 60
days of discharge in patients who have been hospitalized for influenza?
H02: There is not a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
Ha2: There is a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
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Does the use of prescription antivirals and/or prescription antibiotics predict CDI
within 60 days of discharge in patients who have been hospitalized for influenza?
H03: The use of prescription antivirals and/or prescription antibiotics does not
predict CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha3: The use of prescription antivirals and/or prescription antibiotics does predict
CDI within 60 days of discharge in patients who have been hospitalized for influenza.
In Chapter 4, I examine the data collection details, population sampling, data
analysis results with tables, and the research questions’ findings summarization.
Data Collection
Data were generated using a proprietary laboratory based surveillance system of
secondary data from a cohort of U.S. hospitals. The initial steps to obtain the data set
required a query of hospitals using both the CareFusion MedMined Surveillance Advisor
module and Patient Event Advisor module from the total number of hospitals that
subscribe. From the selected segment of hospitals meeting this criteria, custom,
individual VSI reports were written for each site to query search criteria of inpatients
with influenza and Clostridium difficile across time frames to incorporate the 60 days of
discharge. Population data were extracted based on meeting the criteria of adult patient
age and hospitalized with a postive test for influenza. Multiple years were queried to
obtain data across many flu seasons using years 2005 to 2014. The years selected for each
hospital’s VSI report was based on each individual site’s specific available data for
review. This was based on the database findings of how far back in time (years) data had
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been stored in the repository. This was also joined to the database utilization of the
Patient Event Advisor module that houses the pharmacy portion of the patient records.
The development of CDI within 60 days of discharge was based on the date listed in the
database for the patient discharge timeframe and a positive laboratory test for Clostridium
difficile.
After the reports were generated, the sample population was selected. The
population was randomly chosen without regard for gender. States in which hospitals
were located were randomly dispersed within the census bureau regions. Patients who
were selected into the population data set were then queried using the Patient Event
Advisor module using their specific MRN and time frame of hospital admission. Specific
pharmacy data were retrieved, and the data elements of antiviral and antibiotics
prescribed and dispensed were gathered. The exact names of the antivirals and individual
antibiotics were identified and logged for data analysis. The population selected was
chosen and verified based on positive laboratory test for influenza and Clostridium
difficile. Cases were coded according to the dichotomous dependent variable (0 = No
CDI, 1 = Yes CDI). The independent variables of antibiotic use, antiviral use, and either
antiviral use, antibiotic use, or both used were coded No = 0 and Yes = 1. The population
selected was also logged according to the four census regions: Northeast, Midwest,
South, and West. Data were assessed for missingness, reviewed for accuracy, and cleaned
prior to entry into SPSS to perform regression testing.
Although the number of hospitals that subscribe to the MedMined database is
over 400, a query of the potential sample dataset revealed some of the hospitals that
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subscribed to use of both MedMined modules did not have complete data variables
populated for this study. Hospitals that did not have data in both modules for the time
year periods required for the study were not used, resulting in the final study sample
frame of 25 hospitals. While this limitation was a factor for not achieving the large
sample size, the final study population was 147 patients, which met the minimum sample
size requirement to achieve 80% power. After reviewing the diagnosis field in the data
set and finding it unreliable and inconsistently documented, it was deemed best to use
results of a positive laboratory tests for the criteria of both influenza and Clostridium
difficile to ensure accuracy and consistency in the data collection.
Results
Data were gathered from 147 participants and entered in to SPSS version 22.0 for
Windows. Descriptive statistics were conducted to outline the sample demographics.
Frequencies and percentages were calculated for gender and regional representation
according to the United States Census Bureau regions. Means (standard deviations) and
ranges were used to describe the central tendency and spread of ages within the sample.
Of the 147 study participants, 117 (79.6%) participants received antibiotics, 106
(72.1%) received antivirals, 130 (88.4%) received antibiotics and/or antivirals, and 17
(11.6%) patients developed Clostridium difficile within 60 days of discharge. Out of the
17 patients who developed CDI, 11 had received both antibiotics and antivirals, four had
received antibiotics only, and two did not receive antibiotics or antivirals.
The overall sample had an average age of 62.9 years (SD = 19.7), with a range
from 19 to 101 years. The participants who developed Clostridium difficile ages ranged
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from 36 to 91 years with an average age of 67.6 years (SD = 16.5), compared with the
average age of 62.3 years (SD = 19.9) for participants who did not develop Clostridium
difficile. In Table 2 the distribution of samples positive with Clostridium difficile by
region, gender, age and antimicrobial receipt are presented.
Table 2
Clostridium difficile Positive Sample by Region, Gender, Age, and Antimicrobial Receipt
(n=17)
Region
Midwest
Midwest
Midwest
Midwest
Midwest
Midwest
Northeast
Northeast
Northeast
Northeast
Northeast
Northeast
South
South
West
West
West

Gender
Female
Male
Female
Male
Male
Male
Female
Male
Male
Male
Male
Male
Female
Male
Female
Female
Male

Age
91
86
83
73
69
36
64
89
83
77
59
47
56
58
68
37
74

Antibiotic
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Antiviral
No
Yes
No
Yes
No
Yes
No
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes

The participant geographic region sample revealed (n = 44, 29.9%) from the
Midwest region, Northeast region (n = 42, 28.6 %), South (n = 33, 22.4%), and the West
(n = 28, 19.0%). Next, each region was examined for frequency of Clostridium difficile.
The highest percentages for regions from which multiple participants were gathered were
the Midwest and Northeast. A total of 12 participants, six participants from the Midwest
and six participants from the Northeast developed Clostridium difficile, representing a
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total of approximately 8% of the 147 participants. In the West region, three participants
of the 147 total developed Clostridium difficile, representing 2.0%, and two participants
of the 147 total developed Clostridium difficile, representing 1.4% from the South.
Within the regions, six participants of the 44 total participants from the Midwest,
13.6%, and six participants of the 42 from the Northeast, 14.2%, developed Clostridium
difficile. Overall, approximately 28% from these regions were diagnosed within 60 days
from discharge with CDI. In the West region, three of the 28 (10.7%), had Clostridium
difficile diagnosis, and for participants from the South region, two of the 33 (6.1%) were
diagnosed from this sample with Clostridium difficile within 60 days.
The sample was approximately equally divided between males (n = 72, 48.9%)
and females (n = 75, 51.0%). Males had a slightly higher rate of Clostridium difficile
diagnosis than females for the sample (7.5% vs. 4.1%). Within the gender specific
categories, male gender diagnosed with Clostridium difficile is 15.3% and female gender
with Clostridium difficile is 8.0%. The categorical demographic frequency and
percentages of the study participants for each region and gender are presented in Table 3
along with the region and gender specific percentages with Clostridium difficile.
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Table 3
Frequency for Sampled Gender and Regions and Percent With Clostridium difficile
(N=147)
Demographic
Gender frequency
Male
Female
Gender percent with Clostridium difficile
Male
Female
Gender specific percent with Clostridium difficile
Male (n=72)
Female (n=75)
Region frequency
Midwest
Northeast
South
West
Region percent with Clostridium difficile
Midwest
Northeast
South
West
Region specific percent with Clostridium difficile
Midwest (n=44)
Northeast (n=42)
South (n=33)
West (n=28)

n

%

72
75

48.9
51.0

11
6

7.5
4.1

11
6

15.3
8.0

44
42
33
28

29.9
28.6
22.4
19.0

6
6
2
3

4.1
4.1
1.4
2.0

6
6
2
3

13.6
14.2
6.1
10.7
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Research Question 1
Is there a relationship between use of prescription antivirals and CDI within 60
days of discharge in patients who have been hospitalized for influenza?
H01: There is not a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha1: There is a statistically significant association between use of prescription
antivirals and CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
To examine Research Question 1, a binary logistic regression was conducted with
the use of prescription antivirals predicting instances of Clostridium difficile within 60
days of discharge while controlling for age and gender. Results of the binary logistic
regression were not statistically significant (χ2(3) = 3.38, p = .336, Negelkerke R2 = .05)
indicating that age, gender, and the use of antivirals were not significant predictors of
Clostridium difficile diagnosis within 60 days from discharge. Thus, the null hypothesis
was retained and no further interpretations were made. Results of the binary logistic
regression with antiviral use predicting Clostridium difficile within 60 days of discharge
are presented in Table 4.
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Table 4
Binary Logistic Regression With Antiviral use Predicting Clostridium Difficile 60 Days
After Discharge

Predictor

B

Antiviral use
0.52
Age
0.02
Gender
0.61
Note. Female referent group.

SE

Wald χ2

p

OR

0.81
0.02
0.56

0.42
1.16
1.21

0.52
.282
.271

1.69
1.02
1.84

95% CI
Lower Upper
0.34
0.99
0.62

8.28
1.05
5.48

To examine the first regression model, the Hosmer Lemeshow test was used in
conjunction with the classification table to determine the model’s fit. For this model, the
Hosmer Lemeshow test did not indicate a significant difference between the final
regression model and the observed data (χ2(7) = 6.80, p = .450). The classification table
was examined to further detail the model fit that suggested that 88.3% of the participants’
placement in the outcome groups was accurately predicted. However, this may be due to
the fact that the model consistently classified all participants into the larger group, which
contained 88.3% of the sample. The nonsignificant predictors (p > .05 for each) indicated
that the model could not use the independent variables to accurately classify participants
into a group of Clostridium difficile within 60 days versus no Clostridium difficile within
60 days. Table 5 provides the classification table for this regression model.
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Table 5
Classification Table for Antiviral Use as Examined in Research Question 1

Observed

No CDI

No CDI
128
CDI within 60 days
17
Note. Overall correct classification of 88.3%.

Predicted
CDI within 60 days
0
0

% Correct
100
0

Research Question 2
Is there a relationship between use of prescription antibiotics and CDI within 60
days of discharge in patients who have been hospitalized for influenza?
H02: There is not a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
Ha2: There is a statistically significant association between use of prescription
antibiotics and CDI within 60 days of discharge in patients who have been hospitalized
for influenza.
To examine Research Question 2, a binary logistic regression was conducted with
the use of prescription antibiotics predicting instances of Clostridium difficile within 60
days of discharge while controlling for age and gender. Results of the binary logistic
regression were not statistically significant (χ2(3) = 3.75, p = .290, Negelkerke R2 = .05)
indicating that age, gender, and the use of antibiotics were not significant predictors of
Clostridium difficile diagnosis within 60 days from discharge. Thus, the null hypothesis
was retained and no further interpretations were made. Results of the binary logistic
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regression with antibiotic use predicting Clostridium difficile within 60 days of discharge
are presented in Table 6.
Table 6
Binary Logistic Regression With Antibiotic Use Predicting Clostridium Difficile 60 Days
After Discharge

Predictor

B

Antibiotic use
-0.52
Age
0.02
Gender
0.78
Note. Female referent group.

2

SE

Wald χ

p

OR

0.56
0.01
0.55

0.85
1.10
2.02

.357
.295
.155

0.60
1.02
2.19

95% CI
Lower Upper
0.20
0.99
0.74

1.79
1.04
6.42

To examine the second regression model, the Hosmer Lemeshow test was used in
conjunction with the classification table to determine the model’s fit. For this model, the
Hosmer Lemeshow test did not indicate a significant difference between the final
regression model and the observed data (χ2(7) = 1.97, p = .961). The classification table
was examined to further detail the model fit which suggested that 88.3% of the
participants’ placement in the outcome groups was accurately predicted. However, this
may be due to the fact that the model consistently classified all participants into the larger
group, which contained 88.3% of the sample. The nonsignificant predictors (p > .05 for
each) indicated that the model could not use the independent variables to accurately
classify participants into a group of Clostridium difficile within 60 days versus no
Clostridium difficile within 60 days. Table 7 provides the classification table for this
regression model.
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Table 7
Classification Table for Antibiotic Use as Examined in Research Question 2

Observed

No CDI

No CDI
128
CDI within 60 days
17
Note. Overall correct classification of 88.3%.

Predicted
CDI within 60 days

% Correct

0
0

100
0

Research Question 3
Do the use of prescription antivirals and/or prescription antibiotics predict CDI
within 60 days of discharge in patients who have been hospitalized for influenza?
H03: The use of prescription antivirals and/or prescription antibiotics does not
predict CDI within 60 days of discharge in patients who have been hospitalized for
influenza.
Ha3: The use of prescription antivirals and/or prescription antibiotics does predict
CDI within 60 days of discharge in patients who have been hospitalized for influenza.
To examine Research Question 3, a binary logistic regression was conducted with
the use of prescription antivirals or antibiotics predicting instances of Clostridium
difficile within 60 days of discharge while controlling for age and gender. For this
regression, the variable of antiviral or antibiotic use was coded such that 0 = neither
antibiotic nor antivirals used, and 1 = either antibiotics, antivirals, or both used. Results
of the binary logistic regression were not statistically significant (χ2(3) = 3.07, p = .382,
Negelkerke R2 = .04) indicating that age, gender, and the use of antivirals or antibiotics
were not accurate predictors of Clostridium difficile diagnosis within 60 days from
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discharge. Thus, the null hypothesis was retained and no further interpretations were
made. Results of the binary logistic regression with antiviral and antibiotic use predicting
Clostridium difficile within 60 days of discharge are presented in Table 8.
Table 8
Binary Logistic Regression With Antibiotic and/or Antiviral Use Predicting Clostridium
Difficile 60 Days After Discharge

Predictor

Antiviral and/or Antibiotic
use
Age
Gender
Note. Female referent group.

95% CI
Lower Upper

B

SE

Wald
χ2

p

OR

-0.32

0.83

0.15

.701

0.73

0.14

3.72

0.02
0.75

0.01
0.55

1.13
1.84

.287
.175

1.02
2.12

0.99
0.72

1.04
6.29

To examine the third regression model, the Hosmer Lemeshow test was used in
conjunction with the classification table to determine the model’s fit. For this model, the
Hosmer Lemeshow test did not indicate a significant difference between the final
regression model and the observed data (χ2(8) = 5.49, p = .705). The classification table
was examined to further detail the model fit which suggested that 88.3% of the
participants’ placement in the outcome groups was accurately predicted. However, this
may be due to the fact that the model consistently classified all participants into the larger
group, which contained 88.3% of the sample. The non-significant predictors (p > .05 for
each) indicated that the model could not use the independent variables to accurately
classify participants into a group of Clostridium difficile within 60 days versus no
Clostridium difficile within 60 days. Table 9 provides the classification table for this
regression model.
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Table 9
Classification Table for Use of Antivirals and/or Antibiotics as Examined in Research
Question 3

Observed

No CDI

Predicted
CDI within 60 days

No CDI
128
CDI within 60 days
17
Note. Overall correct classification of 88.3%.

0
0

% Correct
100
0

Summary of Results
Three logistic regressions were conducted to determine a possible relationship
between the use of antiviral or antibiotic medication with development of Clostridium
difficile within 60 days of discharge from the hospital while controlling for the effect of
gender and age. Results of the first logistic regression indicated there was no impact of
antiviral use on development of Clostridium difficile within 60 days of discharge. Results
of the second logistic regression indicated there was no impact of antibiotic use on
development of Clostridium difficile within 60 days of discharge. Results of the final
logistic regression examined cases of antiviral and/or antibiotic use and indicated there
was no statistically significant impact of either medication on development of
Clostridium difficile within 60 days of discharge.
In Chapter 5 the study findings will be examined and interpreted further to
provide comparisons to the literature review, analyze the findings in the context of the
theoretical framework, describe recommendations for future studies based on this study’s
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findings and limitations, and explore the study’s impact for social change and
recommendations for healthcare practice.
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of the study was to to examine the temporal progression of CDI
incidence and the possible influence that the seasonal variation of influenza and antibiotic
and antiviral use has on the incidence of CDI. An enhanced understanding could be
determined about the relationship of CDI and seasonal influenza as well as the
role/influence of antibiotic use and selection. The study’s significance may be to further
contribute to the growing body of knowledge of the implications that antibiotic use has
on CDI. In this study, I examined if the overuse and/or inappropriate use of antibiotics
has an impact on the development of CDI during seasonal disease outbreaks of influenza.
Three logistic regressions were conducted to determine the relationship between
the use of antiviral or antibiotic medication with development of Clostridium difficile
within 60 days of discharge from the hospital while controlling for the effect of gender
and age. The first logistic regression results indicated there was no impact of antiviral use
on development of Clostridium difficile within 60 days of discharge. Next, the second
logistic regression indicated there was no impact of antibiotic use on development of
Clostridium difficile within 60 days of discharge. Finally, the third logistic regression
results indicated when cases of antiviral and/or antibiotic use were examined, there was
no statistically significant impact of either medication on development of Clostridium
difficile within 60 days of discharge.
Interpretation of the Findings
The data from this study resulted in a representative population based on the
literature review. The highest rates of influenza and CDI occur among persons 65 years
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and older, with over two-thirds of the patients with CDI being elderly (APIC, 2013;
Elixhauser & Jhung, 2008). This study population’s average age was 62.9 years old, with
an age range of 19 to 101. Among the influenza positive study population who developed
Clostridium difficile, the average age was 67.6 years old, similar to the results by APIC,
2013 and Elixhauser and Jhung, 2008.
Additionally noted by Elixhauser and Jhung are changes in CDI epidemiology
regional incidence based on a review of United States hospital discharge data, finding the
Northeastern rate was 2 times higher than the West, which had the lowest rate. The
frequencies in the Midwest and South were 69% and 42% higher than the West
frequency, respectively (Elixhauser & Jhung ,2008). I found a slight difference in the
highest percentage of Clostridium difficile coming from the Midwest (4%) and Northeast
(4%) equally and the West (2%) was slightly higher than the South (1%), which includes
taking into account the study’s design of more sampling in the Northeast, Midwest, and
South than the West. Although rates of CDI related hospital stays are higher in females
than males (APIC, 2013), this study revealed the incidence of CDI within 60 days of
discharge among hospitalized patients with the flu nearly double in males (7%) versus
females (4%). The study population was nearly equal sample population of males versus
females. This difference in gender incidence was in contrast to cited findings (APIC,
2013) and therefore suggests the need for further study.
As described in Chapter 2, using the wheel model of man-environment
interactions framework, the study increased understanding determinents of CDI, seasonal
influenza, and the role/influence of antibiotic use and selection. The study population of
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adults (host) at the center of the three sections of the environment illustrated the role in
disease development of CDI as many medical decisions start with the individual. The
development of influenza is based on the lack of vaccine receipt, naïve host, or a vaccine
mismatch due to a differing circulating/novel influenza strain (CDC, 2009). This section
weighs heavy in the biological section, as does receipt of a good strain match of vaccine
for influenza prevention. Additionally, there can be biological factors of a dose-response
relationship in the development of influenza with the occurrence of influenza based
exposure to the associated influenza strain and the proportion of vaccine match for those
who received it (CDC, 2009; Glezen, 2006). Admission to the hospital or need to seek
medical intervention for influenza is in the social and biological sections. This can have
social constructs of individual, family, or cultural groups influencing the health seeking
behavior and decisions to seek treatment. The study database was not accessible for
determinants of reasons for hospitalization or social constructs to seek care. The physical
environment includes exposure to Clostridium difficile spores in the physical hospital
environment and the social aspects include if the physician prescribes antibiotics that may
alter the host gut to develop CDI as well as the host request and acceptance of antibiotics.
Although this is true, the environmental factors that influenced CDI development were
not explored in this study. The physican’s desire to use antibiotics may be based on the
need to provide comprehensive coverage for all upper and lower respiratory conditons
without a clear etiology, not having or waiting for influenza testing results prior to
administration of antibiotics for bacterial infections versus antivirals for viral infections
such as influenza, lack of critical thinking, physician’s need to do something for the
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patient, or maintain patient satifaction as they request medications (Bonner et al., 2003;
Linder et al., 2006). Social aspects of care for the study population by the medical
providers would greatly influence this portion of the wheel. This area of the physicians’
use of antibiotics in the face of a positive influenza result could not be explored fully due
to database limitations; it was not a full medical record with access to documentation of
coinfection or other signs and symptoms.
There were clear cases of study individuals who did not receive any antibiotics or
antivirals and cases who received antibiotics only without antivirals despite the fact they
were test positive for influenza. Antivirals are the appropriate choice to treat influenza.
They can reduce the duration of influenza symptoms by 1 to almost 3 days and reduce
complications that require the use of antibiotics (Linder et al., 2005). Additionally,
antiviral use may decrease hospitalization and mortality. Linder et al. found the use of
antiviral medications for management of influenza important, given influenza vaccine
receipt and effectiveness can vary. The study data demonstrated within this hospital
cohort and sample population that the recommended administration of antiviral
medication was not consistent among influenza positive patients. Of the 147 study
participants, 117 participants received antibiotics, 106 received antivirals, and 130
received antibiotics and/or antivirals. Each of the study participants had laboratory
evidence of positive influenza; with this diagnostic certainty, the sample population
should have all received antiviral medication according to practice recommendations
(ACIP, 2011). The study data confirmed findings in the literature (Falsey et al., 2007;
Linder et al., 2005) of the utilization of antibiotics with a lab confirmed influenza
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diagnosis and antibiotic use continued during the hospital stay. Although it is true that
there were database limitations of no access to indicators of antibiotic use that could be
found in the full medical record, documentation of coinfection, or other signs and
symptoms, the data could be extrapolated based on the literature that physicians
prescribed inappropriate antibiotics about 26% of the time (Linder et al., 2005).
Additionally, this study illustrated the evidence that physicians do not alter their clinical
decisions for treatment of influenza when positive results are readily available and treated
with antibiotics. This confirmed the findings of Falsey et al. that with sound medical
evidence, practitioners justify the choice to continue antibiotic use and supported the
work by Linder et al. that physicians prescribe inappropriate antibiotics to patients with
an influenza diagnosis. The study data contradicted the findings of Bonner et al. (2003)
that physicians who have knowledge of influenza test results used less antibiotics and
prescribed more antiviral medications. In this study, I found the physicians had evidence
of positive influenza test results documented in the microbiology data on each individual
patient. The lab tests were ordered, testing was performed in the clinical laboratory, and
the results were available for physicians to utilize while making medical decisions for
care and treatment. Based on the lab test results, the need to order and dispense
medication, such as antivirals and antibiotics, may be indicated. The study population of
147 participants were all positive for influenza, yet 117 (79.6%) participants received
antibiotics, 106 (72.1%) received antivirals, 130 (88.4%) received antibiotics and/or
antivirals and 17 (11.6%). The 17 patients who developed Clostridium difficile within 60
days of discharge, 11 had received both antibiotics and antivirals, four had received

73
antibiotics only and two did not receive antibiotics or antivirals. Therefore, my study
findings indicate more antibiotics and less antivirals are prescribed when physicians have
knowledge of influenza test results.

Limitations of the Study
The data used in this study were collected for patient care and not for research.
The study was limited to the association of data and did not allow for a cause and effect
inference because I did not directly collect the data used for this research study. An
observational, nonexperimental design limits the interpretation of the results (McPherson
& Bunker, 1991). Use of these data for the purpose of a research study revealed
limitations but did allow for data analysis within the database limitations to answer the
research questions. Additionally, the database did not include signs and symptoms of
patients’ medical conditions or chief complaints, detailed documentation of underlying
medical conditions that can be exacerbated by influenza infection, or queried for
secondary infections, coinfections, or complications from influenza, such as pneumonia.
With this in mind, sign and symptom information, along with documentation of
coinfections and complications from influenza, did not allow me to extrapolate definitive
clinical implications for the use of antibiotics in the sample population hospitalized with
positive influenza. Moreover, documentation or knowledge of influenza and
pneumococcal vaccine receipt was limited to only the data recorded in the medication
module; therefore, vaccine receipt from anywhere other than the hospital’s dispensing
data could not be queried for the study population. This leads to the patient’s receipt of
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vaccines given elsewhere to remain unknown. The research study did not use vaccine
reciept as a variable. Extraction of the available data set used for the research was limited
to the hospital’s geographic location, laboratory results, admitting diagnosis, medication
orders and dispensing, patient age, and gender.
Another study limitation was the sample size. As indicated by the calculation
described in Chapter 3, the study sample collected would be sufficient; however, this
depended on the distribution of the outcome and size of the effect. The study revealed
few CDI, so the lack of significant findings may have been influenced by two factors.
The effect sizes were small and therefore impacted the study power.
I used a proprietary database from a set of hospitals that pay for the electronic
surveillance system and pharmacy modules. The database used was taken at face value
for data accuracy from the hosted hospital documentation and electronic results. Paid
services of electronic surveillance and pharmacy medication modules made this group of
hospitals unique in terms of their commitment to infection prevention data collection and
antimicrobial monitoring. As a result, increased sampling bias may have been introduced
from this database being used as a research cohort than that seen in random sampling,
indicating that the sample may not have been representative of the United States
population.
Recommendations
Findings from this research revealed the need to further study populations of
influenza positive patients. Specifically, future studies should seek access to detailed
medical records and determine if the use of antibiotics was clinically indicated in addition
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to antiviral use across a large geographic cohort. Pneumococcal vaccine and seasonal
influenza vaccine receipt could be comprehensively researched in the influenza positive
population as factors that may influence the use of antibiotics and as additional study
variables.
Consistent with the literature in Chapter 2, Falsey et al. (2007) studied the impact
of rapid diagnosis testing and the management of adults who were hospitalized with
influenza; rapid influenza testing leads to reduced antibiotic use in hospitalized patients.
Falsey et al. found positive influenza testing was associated with modest withholding or
discontinuing antibiotics; however, a significant portion of the test positive patients at
low risk for bacterial infection continued to receive antibiotics. Physicians were surveyed
to assess the beliefs of being comfortable to discontinue antibiotics in patients with
negative chest x-rays and negative bacterial cultures, and two thirds of the respondents
believed they would be (Falsey et al., 2007). Medical record review, however, found that
in practice these physicians did not discontinue antibiotic use (Falsey et al., 2007).
Physicians are concerned about secondary bacterial infections with an influenza diagnosis
and the ability to distinguish concomitant bacterial or viral infections during peak seasons
for respiratory illness (Falsey et al., 2007). Even with sound medical evidence of no
secondary or concomitant respiratory illness or disease, practitioners justified their choice
to continue antibiotic use.
Several studies have shown that diagnosis and treatment of influenza is not
consistent among physicians. Linder et al. (2005) found that physicians prescribed
inappropriate antibiotics to 26% of patients, and physicians prescribed antiviral
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medication to 19% of patients with an influenza diagnosis. Similar results from a study
by Bonner et al. (2003) illustrated these same findings. As the literature suggests, there is
clearly a need to further study the effects of antibiotic use during the influenza season
among patient populations positive for influenza and the subsequent development of CDI
outcome.
Research could be expanded to include hospitals not using this proprietary
surveillance and pharmacy module to identify a more representative population across the
United States. A study that would include a larger sample size population has the
potential to identify CDI among a cohort altering the distribution of the outcome and size
of the effect, while increasing the power. Moreover, the effect of age as a variable could
be further studied using categorization of age groups among the study population, such as
distribution categories of ages from 18 to age 65 and older.
The role of antibiotic induced Clostridium difficile diarrhea, infection, and colitis
has been well documented ( Bartlett, 2011; Gaynes et al., 2004; Gerding, 2004; Nelson &
Williams, 2007) while the discrete use of antivirals in the development of CDI has not
(Colarian, 1988; Gellad et al., 2007; Gorschlüter et al., 2001; Pulvirenti et al., 2002;).
Additional study of influenza positive populations using specific United States licensed
prescription antiviral agents to treat influenza would add to the body of knowledge
identified from this literature gap.
Implications
The results of this study offered an understanding of Clostridium difficile
epidemiology in this unique influenza positive population and significant implications for
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social change. Better understanding leads to new areas of inquiry and further study. The
primary goal of antimicrobial stewardship is to improve clinical patient outcomes and
minimize unintended adverse consequences due to inappropriate selection, dosing, and
duration of these medication therapies. The incidence of CDAD before and after
implementing antibiotic stewardship programs has been described across the United
States with similar results (AHRQ, 2012). The removal or reducing the use of an
offending antimicrobial agent can result in decreased CDAD (Garey, 2011; Nuila et al.,
2008). Although antimicrobial stewardship has become more common among hospitals,
standardization of protocols and what stewardship details encompass are still being
formulated. This has been fueled by recent governmental attention to improve antibiotic
stewardship according to the metrics outlined within President Obama’s Executive OrderCombating Antibiotic Resistant Bacteria (The White House, 2014). This research study
revealed that there were inconsistencies in antiviral delivery and the need to further study
the overall use of antibiotics in influenza positive populations, which can serve as a
platform for implementing antimicrobial stewardship efforts.
Knowledge from this epidemiologic study of seasonality of disease and antibiotics
may have an influence at local and organizational levels. Healthcare providers may
benefit from recognizing the effect that antibiotic delivery in hospitals has through more
informed choices for use and pharmacologic recommendations. Increasing antibiotic
stewardship may considerably reduce morbidity and mortality associated with CDI.
There is a need for research and studies of this kind to contribute to the literature in order
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for there to be implementation of comprehensive evidence-based Clostridium difficile
measures.
Antibiotic resistance and CDI are health care issues that affect the hospitalized
patient and may have implications for affecting the general public once the patient is
released from a healthcare setting, such as exposing the community population and
environment to antibiotic resistance and CDI. Individuals need to increase their
awareness of vaccine receipt to reduce the potential to contract influenza and spread to
others. Additionally, individuals need to be an active participant in their own medical
care and seek medical attention quickly to be diagnosed with influenza and receive the
appropriate antivirals to lessen the severity and duration of illness. This action may
reduce hospitalizations and risks for influenza complications. Individuals may also
influence receipt of antibiotics by demanding them from medical care providers when
they are not medically indicated, thereby ultimately affect CDI development. Families
may be affected by the vaccine receipt in households as described in literature through
herd immunity. Herd protection of a family or group may occur when a large proportion
of individuals from that group are immune or immunized to influenza reducing exposure
of those susceptible to the flu. The importance of vaccine receipt among family/groups
and seeking diagnostic medical care and appropriate treatment for influenza has been
recognized as an integral part of reducing household and group setting transmission.
Although this study did not have access to data of vaccine receipt specifically, the study
variables did include antiviral and antibiotic receipt among hospitalized patients with
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influenza. As a result, hospital medical staff, families, groups and individuals may benefit
from the findings.
Conclusion
The purpose of this quantitative study was to examine the temporal progression of
CDI incidence and possible influence of seasonal variation of influenza and antibiotic and
antiviral use has on the incidence of CDI. The study aspired to enhance understanding
about the relationship of CDI and seasonal influenza and the role/influence of
antibimicrobial use and selection. Although the study findings did not prove to be
significant for the three research questions with the premise that seasonal influenza leads
to increased prescribing of antimicrobial agents which can lead to increased CDI; there
was evidence to support recommended administration of antiviral medication was not
consistent among influenza positive patients. Furthermore, the study indicated seasonal
antimicrobial use that coincided with seasonal influenza did enable the identification of
inappropriate prescribing patterns for antimicrobial agents. The future of antimicrobial
stewardship is targeted Clostridium difficile reduction efforts as a complementary
strategy to decrease CDI frequency by adressing inappropriate antibiotic use.
Consequently, this study illustrated the need to highlight on the primary goals of
antimicrobial stewardship: to focus on reducing inappropriate antimicrobial use and
ultimately minimizing the unintended adverse consequences of this practice.
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